Teleflex (TFX) 10-K1 Mar 222021 FY Annual reportFinancial data

Company Profile

Cover page

Cover page - USD ($)	12 Months Ended
Cover page - USD ($)	Dec. 31, 2021	Feb. 22, 2022	Jun. 27, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-5353
Entity Registrant Name	TELEFLEX INCORPORATED
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-1147939
Entity Address, Address Line One	550 East Swedesford Road, Suite 400
Entity Address, City or Town	Wayne
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19087
City Area Code	610
Local Phone Number	225-6800
Title of 12(b) Security	Common Stock, par value $1.00 per share
Trading Symbol	TFX
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 11,995,331,611
Entity Common Stock, Shares Outstanding		46,870,014
Documents Incorporated by Reference	Certain provisions of the registrant’s definitive proxy statement in connection with its 2022 Annual Meeting of Stockholders, to be filed within 120 days of the close of the registrant’s fiscal year, are incorporated by reference in Part III hereof.(1) For purposes of this computation only, the registrant has defined “affiliate” as including executive officers and directors of the registrant and owners of more than five percent of the common stock of the registrant, without conceding that all such persons are “affiliates” for purposes of the federal securities laws.
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Central Index Key	0000096943

Audit Information

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2021
Audit Information [Abstract]
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Philadelphia, Pennsylvania
Auditor Firm ID	238

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Net revenues	$ 2,809,563	$ 2,537,156	$ 2,595,362
Cost of goods sold	1,259,961	1,212,282	1,186,357
Gross profit	1,549,602	1,324,874	1,409,005
Selling, general and administrative expenses	860,085	743,568	851,766
Research and development expenses	130,841	119,747	113,857
Restructuring and impairment charges	21,738	38,491	22,205
Gain on sale of business and assets	(91,157)	0	(6,077)
Income from continuing operations before interest, loss on extinguishment of debt and taxes	628,095	423,068	427,254
Interest expense	56,969	66,494	80,270
Interest income	(1,328)	(1,158)	(1,741)
Loss on extinguishment of debt	12,986	0	8,822
Income from continuing operations before taxes	559,468	357,732	339,903
Taxes (benefit) on income from continuing operations	74,349	21,931	(122,078)
Income from continuing operations	485,119	335,801	461,981
Income (loss) from discontinued operations	331	(621)	(828)
Taxes (benefit) on operating loss from discontinued operations	76	(144)	(313)
Income (loss) from discontinued operations	255	(477)	(515)
Net income	$ 485,374	$ 335,324	$ 461,466
Basic:
Income from continuing operations (in dollars per share)	$ 10.37	$ 7.22	$ 10
Income (loss) from discontinued operations (in dollars per share)	0.01	(0.01)	(0.01)
Net income (in dollars per share)	10.38	7.21	9.99
Diluted:
Income from continuing operations (in dollars per share)	10.23	7.10	9.81
Income (loss) from discontinued operations (in dollars per share)	0	(0.01)	(0.01)
Net income (loss), diluted (in dollar per share)	$ 10.23	$ 7.09	$ 9.80
Weighted average shares outstanding:
Basic (in shares)	46,774	46,488	46,200
Diluted (in shares)	47,427	47,287	47,090

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 485,374	$ 335,324	$ 461,466
Foreign currency:
Foreign currency translation adjustments, net of tax of $(5,563), $6,442 and $(6,270), respectively	(63,191)	59,758	4,195
Foreign currency translation, net of tax	(63,191)	59,758	4,195
Pension and other postretirement benefits plans:
Prior service cost recognized in net periodic cost, net of tax of $232, $(7) and $(20), respectively	(780)	26	62
Unamortized (loss) gain arising during the period, net of tax of $(1,671), $6,101 and $3,817, respectively	5,582	(19,966)	(12,767)
Plan amendments, curtailments, and settlements, net of tax of $—, $(1,067) and $—, respectively	0	3,544	0
Net loss recognized in net periodic cost, net of tax of $(1,988), $(1,694) and $(1,611), respectively	6,555	5,559	5,319
Foreign currency translation, net of tax of $(238), $243 and $15, respectively	610	(610)	(44)
Pension and other postretirement benefits plans adjustment, net of tax	11,967	(11,447)	(7,430)
Derivatives qualifying as hedges:
Unrealized (loss) gain on derivatives arising during the period, net of tax $(27), $234 and $(85), respectively	351	(3,331)	1,062
Reclassification adjustment on derivatives included in net income, net of tax of $62, $(240) and $150, respectively	1,212	2,114	(1,134)
Derivatives qualifying as hedges, net of tax	1,563	(1,217)	(72)
Other comprehensive (loss) income, net of tax	(49,661)	47,094	(3,307)
Comprehensive income	$ 435,713	$ 382,418	$ 458,159

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Foreign currency translation, continuing operations, adjustments, tax	$ (5,563)	$ 6,442	$ (6,270)
Prior service cost recognized in net periodic cost, tax	232	(7)	(20)
Unamortized (loss) gain arising during the period, tax	(1,671)	6,101	3,817
Plan amendments, curtailments, and settlements, tax	0	(1,067)	0
Net loss recognized in net periodic cost, tax	(1,988)	(1,694)	(1,611)
Foreign currency translation, tax	(238)	243	15
Unrealized gain (loss) on derivatives arising during the period, tax	(27)	234	(85)
Reclassification adjustment on derivatives included in net income, tax	$ 62	$ (240)	$ 150

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 445,084	$ 375,880
Accounts receivable, net	383,569	395,071
Inventories	477,643	513,196
Prepaid expenses and other current assets	117,277	115,436
Prepaid taxes	5,545	22,842
Total current assets	1,429,118	1,422,425
Property, plant and equipment, net	443,758	473,912
Operating lease assets	129,653	100,635
Goodwill	2,504,202	2,585,966
Intangibles assets, net	2,289,067	2,519,746
Deferred tax assets	6,820	8,073
Other assets	69,104	41,802
Total assets	6,871,722	7,152,559
Current liabilities
Current borrowings	110,000	100,500
Accounts payable	118,236	102,520
Accrued expenses	163,441	136,276
Payroll and benefit-related liabilities	143,657	122,366
Accrued interest	5,209	7,135
Income taxes payable	83,943	17,361
Other current liabilities	55,633	53,869
Total current liabilities	680,119	540,027
Long-term borrowings	1,740,102	2,377,888
Deferred tax liabilities	370,124	484,678
Pension and postretirement benefit liabilities	45,185	74,499
Noncurrent liability for uncertain tax positions	8,646	10,127
Noncurrent operating lease liabilities	116,033	86,097
Other liabilities	156,765	242,786
Total liabilities	3,116,974	3,816,102
Commitments and contingencies
Shareholders’ equity
Common shares, $1 par value Issued: 2021 — 47,929 shares; 2020 — 47,812 shares	47,929	47,812
Additional paid-in capital	693,090	652,305
Retained earnings	3,517,954	3,096,228
Accumulated other comprehensive loss	(346,959)	(297,298)
Shareholders equity before treasury stock, total	3,912,014	3,499,047
Less: Treasury stock, at cost	157,266	162,590
Total shareholders' equity	3,754,748	3,336,457
Total liabilities and shareholders' equity	$ 6,871,722	$ 7,152,559

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common shares, par value (in dollars per share)	$ 1	$ 1
Common shares, shares issued (in shares)	47,929	47,812

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities of continuing operations:
Net income	$ 485,374	$ 335,324	$ 461,466
Adjustments to reconcile net income to net cash provided by operating activities:
(Income) loss from discontinued operations	(255)	477	515
Depreciation expense	71,758	68,567	64,088
Intangible asset amortization expense	165,604	158,685	149,974
Deferred financing costs and debt discount amortization expense	4,493	4,430	4,307
Loss on extinguishment of debt	12,986	0	8,822
Fair value step up of acquired inventory sold	3,993	1,707	0
Changes in contingent consideration	8,475	(38,164)	53,915
Asset impairment charges	6,739	21,388	6,966
Stock-based compensation	22,937	20,739	26,940
Net gain on sales of business and assets	(91,157)	0	(6,077)
Deferred income taxes, net	(110,239)	(32,675)	(168,594)
Payments for contingent consideration	(230)	(79,801)	(26,092)
Interest benefit on swaps designated as net investment hedges	(19,296)	(19,178)	(18,866)
Other	(36,388)	(26,636)	(5,800)
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(600)	44,748	(59,793)
Inventories	(11,138)	(5,497)	(53,170)
Prepaid expenses and other current assets	(28,410)	(4,323)	(31,023)
Accounts payable, accrued expenses and other liabilities	94,020	646	36,021
Income taxes receivable and payable, net	73,473	(13,294)	(6,531)
Net cash provided by operating activities from continuing operations	652,139	437,143	437,068
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(71,618)	(90,694)	(102,695)
Payments for businesses and intangibles acquired, net of cash acquired	(4,590)	(767,830)	(3,462)
Proceeds from sales of business and assets	224,909	1,400	14,345
Net interest proceeds on swaps designated as net investment hedges	19,154	19,341	18,331
Proceeds from sales of investments	7,300	0	0
Purchase of investments	(18,418)	0	0
Net cash provided by (used in) investing activities from continuing operations	156,737	(837,783)	(73,481)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	400,000	1,513,807	275,000
Reduction in borrowings	(1,034,500)	(938,807)	(528,500)
Debt extinguishment, issuance and amendment fees	(9,774)	(8,440)	(11,635)
Net proceeds from share based compensation plans and the related tax impacts	12,451	18,994	21,206
Payments for contingent consideration	(31,448)	(67,170)	(112,079)
Dividends paid	(63,648)	(63,221)	(62,828)
Proceeds from sale of treasury stock	11,097	0	0
Net cash (used in) provided by financing activities from continuing operations	(715,822)	455,163	(418,836)
Cash flows from discontinued operations:
Net cash (used in) provided by operating activities	(720)	(737)	2,457
Net cash (used in) provided by discontinued operations	(720)	(737)	2,457
Effect of exchange rate changes on cash and cash equivalents	(23,130)	21,011	(3,286)
Net increase (decrease) in cash and cash equivalents	69,204	74,797	(56,078)
Cash and cash equivalents at the beginning of the year	375,880	301,083	357,161
Cash and cash equivalents at the end of the year	$ 445,084	$ 375,880	$ 301,083

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid in Capital	Retained Earnings	Retained EarningsCumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (loss)	Treasury Stock
Beginning Balance (in shares) at Dec. 31, 2018			47,248					1,232
Beginning Balance at Dec. 31, 2018	$ 2,539,978	$ (1,321)	$ 47,248	$ 574,761	$ 2,427,599	$ (1,321)	$ (341,085)	$ (168,545)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2016-13 [Member]
Net income	$ 461,466				461,466
Cash dividends	(62,828)				(62,828)
Other comprehensive income (loss)	(3,307)						(3,307)
Shares issued under compensation plans (in shares)			288					(46)
Shares issued under compensation plans	44,952		$ 288	42,092				$ 2,572
Deferred compensation (in shares)								(4)
Deferred compensation	380			127				$ 253
Ending Balance (in shares) at Dec. 31, 2019			47,536					1,182
Ending Balance at Dec. 31, 2019	2,979,320	$ (791)	$ 47,536	616,980	2,824,916	$ (791)	(344,392)	$ (165,720)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	335,324				335,324
Cash dividends	(63,221)				(63,221)
Other comprehensive income (loss)	47,094						47,094
Shares issued under compensation plans (in shares)			276					(44)
Shares issued under compensation plans	37,732		$ 276	35,223				$ 2,233
Deferred compensation (in shares)								(6)
Deferred compensation	999			102				$ 897
Ending Balance (in shares) at Dec. 31, 2020			47,812					1,132
Ending Balance at Dec. 31, 2020	3,336,457		$ 47,812	652,305	3,096,228		(297,298)	$ (162,590)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	485,374				485,374
Cash dividends	(63,648)				(63,648)
Other comprehensive income (loss)	(49,661)						(49,661)
Shares issued under compensation plans (in shares)			117					(31)
Shares issued under compensation plans	34,453		$ 117	33,989				$ 347
Treasury stock reissued (in shares)								(28)
Treasury stock reissued	11,097			6,349				$ 4,748
Deferred compensation (in shares)								(4)
Deferred compensation	676			447				$ 229
Ending Balance (in shares) at Dec. 31, 2021			47,929					1,069
Ending Balance at Dec. 31, 2021	$ 3,754,748		$ 47,929	$ 693,090	$ 3,517,954		$ (346,959)	$ (157,266)

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Stockholders' Equity [Abstract]
Dividends, per common share (in dollars per share)	$ 1.36	$ 1.36	$ 1.36

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
Summary of significant accounting policies	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Consolidation: The consolidated financial statements include the accounts of Teleflex Incorporated and its subsidiaries (referred to herein as “we,” “us,” “our” and “Teleflex"). Intercompany transactions are eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and reflect management’s estimates and assumptions that affect the recorded amounts. Use of estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenues and expenses during the reporting period. Our estimates have considered the potential impacts stemming from the COVID-19 pandemic, which include increased uncertainty due to the difficulty in predicting the extent and duration of the pandemic. Accordingly, actual results could differ from those estimates. Cash and cash equivalents: All highly liquid debt instruments with an original maturity of three months or less are classified as cash equivalents. The carrying value of cash equivalents approximates the current market value. Accounts receivable: Accounts receivable represent amounts due from customers related to the sale of products and provision of services. Our allowance for credit losses is maintained for trade accounts receivable based on the expected collectability of accounts receivable and losses expected to be incurred over the life of our receivables. Considerations to determine credit losses include our historical collection experience, the length of time an account is outstanding, the financial position of the customer, information provided by credit rating services, as well as the consideration of events or circumstances indicating historic collection rates may not be indicative of future collectability. The allowance for credit losses as of December 31, 2021 and December 31, 2020 was $10.8 million and $12.9 million, respectively. The current portion of the allowance for credit losses, which was $6.0 million and $8.1 million as of December 31, 2021 and December 31, 2020, respectively, was recognized as a reduction of accounts receivable, net. Inventories: Inventories are valued at the lower of cost or net realizable value. The cost of our inventories is determined using the average cost method. Elements of cost in inventory include raw materials, direct labor, and manufacturing overhead. In estimating net realizable value, we evaluate inventory for excess and obsolete quantities based on estimated usage and sales, among other factors. Property, plant and equipment: Property, plant and equipment are stated at cost, net of accumulated depreciation. Costs incurred to develop internal-use computer software during the application development stage generally are capitalized. Costs of enhancements to internal-use computer software are capitalized, provided that these enhancements result in additional functionality. Other additions and those improvements which increase the capacity or lengthen the useful lives of the assets are also capitalized. Composite useful lives for categories of property, plant and equipment, which are depreciated on a straight-line basis, are as follows: buildings — 30 years; machinery and equipment — 3 to 15 years; computer equipment and software — 3 to 10 years. Leasehold improvements are depreciated over the lesser of the useful lives of the leasehold improvements or the remaining lease term. Repairs and maintenance costs are expensed as incurred. Goodwill and other intangible assets: Goodwill and other indefinite-lived intangible assets are not amortized but are tested for impairment annually during the fourth quarter or more frequently if events or changes in circumstances indicate that an impairment may exist. Impairment losses, if any, are included in income from operations. The goodwill impairment test is applied to each of our reporting units. For purposes of this assessment, a reporting unit is an operating segment, or a business one level below an operating segment (also known as a component) if discrete financial information is prepared for that business and regularly reviewed by segment management. However, separate components are aggregated as a single reporting unit if they have similar economic characteristics. In performing the goodwill impairment test, we may assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Qualitative factors may include, but are not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for our products and services, regulatory and political developments, and entity specific factors such as strategies and financial performance. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of a reporting unit is less than its carrying value, we proceed to a quantitative impairment test, described below. Alternatively, we may elect to bypass the qualitative assessment and perform the quantitative impairment test. Under a quantitative impairment test, we compare the fair value of a reporting unit to its carrying value. If the reporting unit fair value exceeds the carrying value, there is no impairment. If the reporting unit carrying value exceeds the fair value, we recognize an impairment loss based on the amount the carrying value of the reporting unit exceeds its fair value. We did not record a goodwill impairment charge for the year ended December 31, 2021. Our intangible assets consist of customer relationships, intellectual property, distribution rights, in-process research and development ("IPR&D"), trade names and non-competition agreements. We define IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and is required be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or upon abandonment. Upon completion of the development project (generally when regulatory approval to market the product that utilizes the technology is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would be written off. We test our indefinite-lived intangible assets for impairment annually, or more frequently if events or changes in circumstances indicate that an impairment may have occurred. Similar to the goodwill impairment test process, we may elect to perform a qualitative assessment. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of the indefinite-lived intangible asset is greater than its carrying amount, the asset is not impaired. If we conclude it is more likely than not that the fair value of the indefinite-lived intangible asset is less than the carrying value, we then proceed to a quantitative impairment test, which consists of a comparison of the fair value of the intangible asset to its carrying amount. Intangible assets that do not have indefinite lives, consisting of intellectual property, customer relationships, distribution rights, certain trade names and non-competition agreements, are amortized over their estimated useful lives, which are as follows: intellectual property, 5 to 20 years; customer relationships, 8 to 27 years; distribution rights, 10 years; trade names, 5 to 30 years; non-competition agreements, 5 to 6 years. The weighted average remaining amortization period with respect to our intangible assets is approximately 15 years. We periodically evaluate the reasonableness of the useful lives of these assets. Long-lived assets: We assess the remaining useful life and recoverability of long-lived assets whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The assessment is based on various analyses, including undiscounted cash flow and profitability projections that incorporate, as applicable, the impact of the asset on the existing business. Therefore, the evaluation involves significant management judgment. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset. Foreign currency translation: Assets and liabilities of subsidiaries with non-United States dollar denominated functional currencies are translated into United States dollars at the rates of exchange at the balance sheet date; income and expenses are translated at the average rates of exchange prevailing during the year. The translation adjustments are reported as a component of accumulated other comprehensive loss. Derivative financial instruments: We use derivative financial instruments primarily for purposes of hedging exposures to fluctuations in foreign currency exchange rates. All instruments are entered into for other than trading purposes. All derivatives are recognized on the balance sheet at fair value. Changes in the fair value of derivatives are recorded in the consolidated statement of comprehensive income as other comprehensive income (loss), if the instrument is designated as part of a hedge transaction. Gains or losses on derivative instruments reported in other comprehensive income (loss) are reclassified to the consolidated statement of income in the period in which earnings are affected by the underlying hedged item. Gains or losses on derivative instruments representing hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, if any, are recognized in the consolidated statement of income for the period in which such gains and losses occur. If the hedging relationship ceases to be highly effective or it becomes probable that an expected transaction will no longer occur, gains or losses on the derivative instrument are recorded in the consolidated statement of income for the period in which either such event occurs. For non-designated derivatives, gains and losses are reported as selling, general and administrative expenses in the consolidated statement of income. Cash flows from derivatives are recognized in the consolidated statements of cash flows in a manner consistent with recognition of the underlying transactions. Share-based compensation: We estimate the fair value of share-based awards on the date of grant using an option pricing model. The value of the portion of the award that is ultimately expected to vest, which is derived, in part, following consideration of estimated forfeitures, is recognized as expense over the requisite service periods. Share-based compensation expense related to stock options is measured using a Black-Scholes option pricing model that takes into account subjective and complex assumptions with respect to the expected life of the options, volatility, risk-free interest rate and expected dividend yield. The expected life of options granted is derived from the vesting period of the award, as well as historical exercise behavior, and represents the period of time that options granted are expected to be outstanding. Expected volatility is based on a blend of historical volatility and implied volatility derived from publicly traded options to purchase our common stock, which we believe is more reflective of market conditions and a better indicator of expected volatility than would be the case if we only used historical volatility. The risk-free interest rate is the implied yield currently available on United States (or "U.S.") Treasury zero-coupon issues with a remaining term equal to the expected life of the option. Forfeitures are estimated at the time of grant based on management’s expectations regarding the extent to which awards ultimately will vest and are adjusted for actual forfeitures when they occur. Income taxes: The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred tax assets and liabilities are recognized to reflect the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, and to reflect operating loss and tax credit carryforwards. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Provision has been made for income taxes on unremitted earnings of subsidiaries and affiliates, except to the extent that such earnings are deemed to be permanently reinvested. Significant judgment is required in determining income tax provisions and in evaluating tax positions. We establish additional provisions for income taxes when, despite the belief that tax positions are supportable, there remain certain positions that do not meet the minimum probability threshold, which is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority. In the normal course of business, we are examined by various federal, state and non-U.S. tax authorities. We regularly assess the potential outcomes of these examinations and any future examinations for the current or prior years in determining the adequacy of our provision for income taxes. Interest accrued with respect to unrecognized tax benefits and income tax related penalties are both included in taxes on income from continuing operations. We periodically assess the likelihood and amount of potential adjustments and adjust the income tax provision, the current tax liability and deferred taxes in the period in which the facts that give rise to an adjustment become known. Pensions and other postretirement benefits: We provide a range of benefits to eligible employees and retired employees, including benefits available pursuant to pension and postretirement healthcare benefits plans. We record annual amounts relating to these plans based on calculations which include various actuarial assumptions such as discount rates, expected rates of return on plan assets, compensation increases, turnover rates and healthcare cost trend rates. We review our actuarial assumptions on an annual basis and make modifications to the assumptions based on current rates and trends when appropriate. The effect of the modifications is generally amortized over future periods. Restructuring costs: We primarily recognize employee termination benefits when payment becomes probable and reasonably estimable because they are provided under an ongoing benefit arrangement and are based on existing plans, historical experience and negotiated settlements of prior plans. Termination benefits provided under one-time termination benefits arrangements, if any, are recognized upon communication to the employee. We recognize charges ratably over the future service period if the employee is required to render service until termination. Other restructuring costs may include facility closure, employee relocation, equipment relocation and outplacement costs and are recognized in the period they are incurred. Contingent consideration related to business acquisitions: In connection with business acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified objectives such as receipt of regulatory approval, commercialization of a product or achievement of sales targets. As of the acquisition date, we record a contingent liability representing the estimated fair value of the contingent consideration that we expect to pay. We remeasure the fair value of our contingent consideration arrangements each reporting period and, based on new developments, record changes in fair value until either the contingent consideration obligation is satisfied through payment upon the achievement of, or the obligation no longer exists due to the failure to achieve, the specified objectives. The change in the fair value is recorded in selling, general and administrative expenses in the consolidated statement of income. A contingent consideration payment is classified as a financing activity in the consolidated statement of cash flows to the extent it was recorded as a liability as of the acquisition date. Any additional amount paid in excess of the amount initially accrued is classified as an operating activity in the consolidated statement of cash flows. Revenue recognition: We primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For the OEM segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which represented 89%, 9% and 2% of our consolidated net revenues, respectively, for the year ended December 31, 2021. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice. We have made the following revenue accounting policy elections and elected to use certain practical expedients: (1) we account for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) we do not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, we expect the period between the time when we transfer a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) we expense costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) we account for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service; (5) we classify shipping and handling costs within cost of goods sold; and (6) with respect to the OEM segment, we have applied the practical expedient to exclude disclosure of remaining performance obligations as the contracts typically have a term of one year or less. The amount of consideration we receive and revenue we recognize varies as a result of changes in customer sales incentives, including discounts and rebates, and returns offered to customers. The estimate of revenue is adjusted upon the earlier of the following events: (i) the most likely amount of consideration expected to be received changes or (ii) the consideration becomes fixed. Our policy is to accept returns only in cases in which the product is defective and covered under our standard warranty provisions. When we give customers the right to return products, we estimate the expected returns based on an analysis of historical experience. The liability for returns and allowances was $15.2 million and $14.6 million as of December 31, 2021 and 2020, respectively. In estimating customer rebates, we consider the lag time between the point of sale and the payment of the customer’s rebate claim, customer-specific trend analyses, contractual commitments, including stated rebate rates, historical experience with respect to specific customers (as we have a history of providing similar rebates on similar products to similar customers) and other relevant information. The reserve for customer incentive programs, including customer rebates, was $26.4 million and $28.5 million at December 31, 2021 and 2020, respectively. We expect the amounts subject to the reserve as of December 31, 2021 to be paid within 90 days subsequent to period-end.

Recently issued accounting stan

Recently issued accounting standards	12 Months Ended
Recently issued accounting standards	Dec. 31, 2021
Accounting Policies [Abstract]
Recently issued accounting standards	Recently issued accounting standards In December 2019, the FASB issued new guidance that simplifies various aspects of accounting for income taxes including those related to the step-up in the tax basis of goodwill, intraperiod tax allocations and the interim period effects of changes in tax laws or rates. The modifications under the new guidance were applied on a prospective basis effective January 1, 2021. The adoption of the new guidance did not have a material effect on the condensed consolidated financial statements.From time to time, new accounting guidance issued by the FASB or other standard setting bodies is adopted as of the specified effective date or, when permitted by the guidance and as determined by us, as of an earlier date. We have assessed recently issued guidance that is not yet effective, except as noted above, and believe the new guidance that we have assessed will not have a material impact on our results of operations, cash flows or financial position.

Net revenues

Net revenues	12 Months Ended
Net revenues	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Net revenues	Net revenues The following table disaggregates revenue by global product category for the year ended December 31, 2021, 2020 and 2019. Year Ended December 31 2021 2020 2019 Vascular access $ 700,240 $ 657,703 $ 600,874 Anesthesia 380,140 302,293 338,413 Interventional 427,500 382,435 427,563 Surgical 377,756 317,200 370,074 Interventional urology 341,661 290,022 290,449 OEM 245,681 220,246 220,717 Other (1) 336,585 367,257 347,272 Net revenues (2) $ 2,809,563 $ 2,537,156 $ 2,595,362 (1) Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products). Certain product lines within the respiratory product category were sold during 2021. See Note 4 for additional information related to the Respiratory business divestiture. (2) The product categories listed above are presented on a global basis, while each of our reportable segments other than the OEM reportable segment are defined based on the geographic location of its operations; the OEM reportable segment operates globally. Each of the geographically based reportable segments include net revenues from each of the non-OEM product categories listed above.

Acquisitions and Divestitures

Acquisitions and Divestitures	12 Months Ended
Acquisitions and Divestitures	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisitions and Divestitures	Acquisitions and Divestitures Divestiture On May 15, 2021, we entered into a definitive agreement to sell certain product lines within our global respiratory product portfolio (the "Divested respiratory business") to Medline Industries, Inc. (“Medline”) for consideration of $286.0 million, reduced by $12 million in working capital not transferring to Medline, which is subject to customary post close adjustments (the "Respiratory business divestiture"). In connection with the Respiratory business divestiture, we also entered into several ancillary agreements with Medline to help facilitate the transfer of the business, which provide for transition support, quality, supply and manufacturing services, including a manufacturing and supply transition agreement (the "MSTA"). On June 28, 2021, the first day of the third quarter of 2021, we completed the initial phase of the Respiratory business divestiture, pursuant to which we received cash proceeds of $259 million. We attributed $33.8 million of the proceeds to our performance obligations pursuant to the MSTA. The resulting liability was measured as the excess of the estimated fair value of the services to be performed over the estimated proceeds we expect to receive over the MSTA term. The significant assumption used to estimate the fair value of the services to be performed is the selection of an appropriate gross margin based on comparable companies. The MSTA liability was recorded within Other current liabilities and Other liabilities in the condensed consolidated balance sheet and the related proceeds will be recognized in net revenues as the services are performed. The second phase of the Respiratory business divestiture will occur once we transfer certain additional manufacturing assets to Medline. Our receipt of $15.0 million in additional cash proceeds is contingent upon the transfer of these manufacturing assets and is expected to occur prior to the end of 2023. We plan to recognize the contingent consideration, and any gain on sale resulting from the completion of the second phase of the divestiture, when it becomes realizable. The following assets and liabilities were sold as part of the initial phase of the Respiratory business divestiture: Assets Inventories $ 26,830 Current assets 26,830 Property, plant and equipment, net 17,006 Intangible assets, net 41,583 Goodwill 35,745 Operating lease assets 1,053 Other assets 94 Noncurrent assets 95,481 Total assets $ 122,311 Liabilities Other current liabilities $ 535 Noncurrent operating lease liabilities 568 Liabilities $ 1,103 As disclosed in Note 8, $35.7 million of goodwill of our Americas, EMEA and Asia reportable operating segments’ goodwill was attributed to the divested respiratory business based on the fair value of the divested respiratory business relative to the fair value of certain of our reporting units. The fair values were estimated using a combination of the discounted cash flows based on projected future earnings (Income Approach) and market multiples of publicly traded companies in similar lines of business (Market Approach). The more significant judgments and assumptions in determining fair value using the Income Approach include the amount and timing of expected future cash flows and the discount rate that was used to estimate the present value of the future cash flows. The more significant judgments and assumptions in determining fair value using the Market Approach include the determination of appropriate revenue and EBITDA multiples based on the selection of appropriate comparable companies. Net revenues attributable to our divested respiratory business recognized prior to the Respiratory business divestiture are included within each of our geographic segments and were $60.7 million during the year ended December 31, 2021 and $138.5 million for the year ended December 31, 2020. For the year ended December 31, 2021, we recognized $51.1 million in net revenues attributed to services provided to Medline in accordance with the MSTA, which are presented within our Americas reporting segment and our Other global product category. Acquisitions On February 18, 2020, we acquired IWG High Performance Conductors, Inc. (HPC), a privately-held original equipment manufacturer of minimally invasive medical products and high performance conductors, for an initial purchase price of $260.0 million. The purchase price was allocated based on the fair values of the assets and liabilities, including goodwill of $107.1 million, intangible assets of $179.0 million and deferred tax liabilities of $43.4 million. The acquisition complements our OEM product portfolio. For the years ended December 31, 2021 and 2020, we recorded post acquisition revenue of $38.6 million and $27.1 million, respectively, related to HPC within our OEM operating segment. On December 28, 2020, we acquired Z-Medica, LLC ("Z-Medica"), a privately held medical device company that manufactures and sells hemostatic (hemorrhage control) products to complement our anesthesia product portfolio. The acquisition included an initial cash purchase price of $500.0 million, with the potential to make an additional payment up to $25 million upon the achievement of certain commercial milestones. The purchase price was allocated based on the fair values of the assets and liabilities, including goodwill of $186.0 million, intangibles assets of $332.0 million and deferred tax liabilities of $32.2 million. For the year ended December 31, 2021, we recorded post acquisition revenue and operating profit of $66.4 million and $21.8 million, respectively, related to Z-Medica across our geographic segments.

Restructuring and other impairm

Restructuring and other impairment charges	12 Months Ended
Restructuring and other impairment charges	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Restructuring and impairment charges	Restructuring and impairment charges Respiratory divestiture plan During the second quarter of 2021, in connection with the Respiratory business divestiture described in Note 4, we committed to a restructuring plan designed to separate the manufacturing operations to be transferred to Medline from those that will remain with Teleflex, which includes related workforce reductions (the “Respiratory divestiture plan”). The plan includes expanding certain of our existing locations to accommodate the transfer of capacity from the sites being transferred to Medline and replicating the manufacturing processes at alternate existing locations. We expect this plan will be substantially completed by the end of 2023. The following table provides a summary of our cost estimates by major type of expense associated with the Respiratory divestiture plan: Total estimated amount expected to be incurred Program expense estimates: (Dollars in millions) Restructuring charges (1) $5 million to $8 million Restructuring related charges (2) $19 million to $22 million Total restructuring and restructuring related charges $24 million to $30 million (1) Substantially all of the charges consist of employee termination benefit costs. (2) Consist of charges that are directly related to the Respiratory divestiture plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold. We expect substantially all of the restructuring and restructuring related charges will result in future cash outlays, the majority of which will be made in 2022 and 2023. Additionally, we expect to incur $22 million to $28 million in aggregate capital expenditures under the plan, which are expected to be incurred mostly in 2022 and 2023. For the year ended December 31, 2021, we incurred $3.3 million in pre-tax restructuring related charges, all of which were recognized in cost of goods sold. 2021 Restructuring plan During the first quarter of 2021, we committed to a restructuring plan designed to streamline various business functions across our segments. The plan was substantially completed by the end of 2021 and we expect future restructuring expenses associated with the program, if any, to be nominal. Footprint realignment plans We have ongoing restructuring programs related to the relocation of manufacturing operations to existing lower-cost locations and related workforce reductions (referred to as our 2019, 2018 and 2014 Footprint realignment plans). The following tables provide a summary of our cost estimates and other information associated with these ongoing Footprint realignment plans: 2019 Footprint realignment plan 2018 Footprint realignment plan 2014 Footprint realignment plan Program expense estimates: (Dollars in millions) Termination benefits $14 to $15 $60 to $65 $13 to $13 Other costs (1) 2 to 2 3 to 4 1 to 2 Restructuring charges 16 to 17 63 to 69 14 to 15 Restructuring related charges (2) 38 to 43 47 to 59 39 to 40 Total restructuring and restructuring related charges $54 to $60 $110 to $128 $53 to $55 Other program estimates: Expected cash outlays $48 to $54 $99 to $122 $43 to $46 Expected capital expenditures $31 to $33 $15 to $16 $26 to $27 Other program information: Period initiated February 2019 May 2018 April 2014 Estimated period of substantial completion 2022 2022 2022 Aggregate restructuring charges $15.6 $62.5 $13.8 Restructuring related charges incurred: For year ended December 31, 2021 $13.0 $10.7 $2.6 Aggregate restructuring related charges $34.1 $27.4 $38.6 (1) Includes facility closure, employee relocation, equipment relocation and outplacement costs. (2) Restructuring related charges represent costs that are directly related to the programs and principally constitute costs to transfer manufacturing operations to the existing lower-cost locations, project management costs and accelerated depreciation. The 2018 Footprint realignment plan also includes a charge associated with our exit from the facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Excluding this tax charge, substantially all of these charges are expected to be recognized within cost of goods sold. The following table summarizes the restructuring reserve activity related to our Respiratory divestiture plan, as well as the 2019, 2018 and 2014 Footprint realignment plans: Respiratory divestiture plan 2019 Footprint realignment plan 2018 Footprint realignment plan 2014 Footprint realignment plan Balance at December 31, 2019 (1) $ — $ 11,870 $ 44,274 $ 3,669 Subsequent accruals — 1,542 5,948 606 Cash payments — (5,532) (4,281) (682) Foreign currency translation and other — 174 4,140 — Balance at December 31, 2020 (1) — 8,054 50,081 3,593 Subsequent accruals 2,694 253 2,476 262 Cash payments (7) (4,982) (4,813) (947) Foreign currency translation and other (86) (19) (3,679) — Balance at December 31, 2021 (1) $ 2,601 $ 3,306 $ 44,065 $ 2,908 (1) The restructuring reserves as of December 31, 2021 , 2020 and 2019 consisted mainly of accruals related to termination benefits. Other costs (facility closure, employee relocation, equipment relocation and outplacement costs) were expensed and paid in the same period. The restructuring and impairment charges recognized for the years ended December 31, 2021, 2020, and 2019 consisted of the following: 2021 Termination benefits Other Costs (1) Total Respiratory divestiture plan $ 2,687 $ 7 $ 2,694 2021 Restructuring plan 7,280 77 7,357 2019 Footprint realignment plan (111) 364 253 2018 Footprint realignment plan 2,335 141 2,476 Other restructuring programs (2) (429) 2,648 2,219 Total restructuring charges 11,762 3,237 14,999 Asset impairment charges — 6,739 6,739 Total restructuring and impairment charges $ 11,762 $ 9,976 $ 21,738 2020 Termination benefits Other Costs (1) Total 2020 Workforce reduction plan $ 8,494 $ 353 $ 8,847 2019 Footprint realignment plan 647 895 1,542 2018 Footprint realignment plan 5,565 383 5,948 Other restructuring programs (3) (72) 838 766 Total restructuring charges 14,634 2,469 17,103 Asset impairment charges — 21,388 21,388 Total restructuring and impairment charges $ 14,634 $ 23,857 $ 38,491 2019 Termination benefits Other Costs (1) Total 2019 Footprint realignment plan $ 13,683 $ 70 $ 13,753 2018 Footprint realignment plan (1,787) 848 (939) Other restructuring programs (4) 787 1,638 2,425 Total restructuring charges 12,683 2,556 15,239 Asset impairment charges — 6,966 6,966 Total restructuring and impairment charges $ 12,683 $ 9,522 $ 22,205 (1) Includes facility closure, contract termination and other exit costs. (2) Includes the 2020 Workforce reduction plan, a program initiated in the third quarter of 2019 and the 2014 Footprint realignment plan. (3) Includes activity primarily related to the 2016 and 2014 Footprint realignment plans. (4) Includes the 2020 Workforce reduction plan, the 2017 Vascular Solutions integration program as well as the 2016 and 2014 Footprint realignment plans. Impairment Charges For the year ended December 31, 2021, we recorded impairment charges of $6.7 million related to our decision to abandon intellectual property and other assets primarily associated with our respiratory product portfolio that were not transferred to Medline as part of the Respiratory business divestiture described in Note 4. For the years ended December 31, 2020 and 2019, we recorded impairment charges of $21.4 million and $7.0 million, respectively, related to our decision to abandon certain intellectual property and other assets associated with our surgical and interventional product portfolio.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories at December 31, 2021 and 2020 consist of the following: 2021 2020 Raw materials $ 146,433 $ 132,370 Work-in-process 81,503 75,874 Finished goods 249,707 304,952 Inventories $ 477,643 $ 513,196

Property, plant and equipment

Property, plant and equipment	12 Months Ended
Property, plant and equipment	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Property, plant and equipment The major classes of property, plant and equipment, at cost, at December 31, 2021 and 2020 were as follows: 2021 2020 Land, buildings and leasehold improvements $ 285,305 $ 272,637 Machinery and equipment 475,040 496,664 Computer equipment and software 191,605 172,913 Construction in progress 49,782 84,336 1,001,732 1,026,550 Less: Accumulated depreciation (557,974) (552,638) Property, plant and equipment, net $ 443,758 $ 473,912

Goodwill and other intangible a

Goodwill and other intangible assets	12 Months Ended
Goodwill and other intangible assets	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets Changes in the carrying amount of goodwill, by reportable operating segment, for the years ended December 31, 2021 and 2020 were as follows: Americas EMEA Asia OEM Total Balance as of December 31, 2019 Goodwill $ 1,883,053 $ 475,772 $ 213,725 $ 4,883 $ 2,577,433 Accumulated impairment losses (332,128) — — — (332,128) 1,550,925 475,772 213,725 4,883 2,245,305 Goodwill related to acquisitions 149,877 22,364 15,698 107,127 295,066 Translation and other adjustments (520) 38,092 8,023 — 45,595 Balance as of December 31, 2020 1,700,282 536,228 237,446 112,010 2,585,966 Goodwill disposed (21,802) (7,537) (6,406) — (35,745) Goodwill related to acquisitions (1,560) (232) (163) — (1,955) Translation and other adjustments (696) (36,310) (7,058) — (44,064) Balance as of December 31, 2021 $ 1,676,224 $ 492,149 $ 223,819 $ 112,010 $ 2,504,202 Intangible assets at December 31, 2021 and 2020 consisted of the following: Gross Carrying Amount Accumulated Amortization 2021 2020 2021 2020 Customer relationships $ 1,328,611 $ 1,377,943 $ (441,059) $ (425,692) In-process research and development 28,158 29,627 — — Intellectual property 1,440,643 1,458,924 (560,740) (479,612) Distribution rights 23,434 23,866 (20,630) (20,280) Trade names 549,269 619,847 (59,249) (65,955) Non-compete agreements 22,783 24,592 (22,153) (23,514) $ 3,392,898 $ 3,534,799 $ (1,103,831) $ (1,015,053) As of December 31, 2021, trade names having a carrying value of $234.7 million are considered indefinite-lived. Acquired IPR&D is indefinite-lived until the completion of the related development project, at which point amortization of the carrying value of the technology will commence. Amortization expense related to intangible assets was $165.6 million, $158.7 million, and $150.0 million for the years ended December 31, 2021, 2020 and 2019, respectively. The estimated annual amortization expense for each of the five succeeding years is as follows: 2022 $ 160,600 2023 154,800 2024 153,000 2025 151,800 2026 148,800

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2021
Leases [Abstract]
Leases	Leases We have operating leases for various types of properties, consisting of manufacturing plants, engineering and research centers, distribution warehouses, offices and other facilities, and equipment used in operations. Some leases provide us with an option, exercisable at our sole discretion, to terminate the lease or extend the lease term for one Maturities of lease liabilities December 31, 2021 2022 $ 26,682 2023 22,790 2024 19,279 2025 14,789 2026 15,307 2027 and thereafter 61,950 Total lease payments 160,797 Less: interest (22,634) Present value of lease liabilities $ 138,163 Supplemental information December 31, 2021 December 31, 2020 Total lease liabilities (1) $ 138,163 $ 108,743 Cash paid for amounts included in the measurement of lease liabilities within operating cash flows $ 29,199 $ 28,276 Right of use assets obtained in exchange for operating lease obligations $ 55,290 $ 8,904 Weighted average remaining lease term 7.9 years 6.7 years Weighted average discount rate 3.7 % 4.0 % (1) The current portion of the operating lease liability is included in other current liabilities .

Borrowings

Borrowings	12 Months Ended
Borrowings	Dec. 31, 2021
Debt Disclosure [Abstract]
Borrowings	Borrowings Our borrowings at December 31, 2021 and 2020 were as follows: 2021 2020 Senior Credit Facility: Revolving credit facility, at a rate of 1.48% at December 31, 2021, and 1.66% at December 31, 2020, due 2024 $ 141,000 $ 350,000 Term loan facility, at a rate of 1.48% at December 31, 2021 and 1.65% at December 31 2020, due 2024 647,500 673,000 4.875% Senior Notes due 2026 — 400,000 4.625% Senior Notes due 2027 500,000 500,000 4.25% Senior Notes due 2028 500,000 500,000 Securitization program, at a rate of 1.00% at December 31, 2021 and 1.24% at December 31, 2020 75,000 75,000 1,863,500 2,498,000 Less: Unamortized debt issuance costs (13,398) (19,612) 1,850,102 2,478,388 Current portion of borrowings (110,000) (100,500) Long-term borrowings $ 1,740,102 $ 2,377,888 Redemption of 4.875% Senior Notes due 2026 On April 29, 2021, we issued a notice of redemption to holders of our outstanding $400 million aggregate principal amount of 4.875% Senior Notes due 2026 (the “2026 Notes”). Pursuant to the notice of redemption, the 2026 Notes were redeemed on June 1, 2021 (the “Redemption Date”) at a redemption price equal to 102.438% of the principal amount of the 2026 Notes plus accrued and unpaid interest up to, but not including, the Redemption Date (the “Redemption Price”). We recognized a loss on extinguishment of debt of $13.0 million as a result of the redemption of the 2026 Notes. Senior credit facility In 2019, we amended and restated our existing credit agreement by entering into a Second Amended and Restated Credit Agreement (the "Credit Agreement"), which provides for a five-year revolving credit facility of $1.0 billion and a term loan facility of $700.0 million (the "Credit Agreement"). Our obligations under the Credit Agreement are guaranteed (subject to certain exceptions and limitations) by substantially all of our material domestic subsidiaries. The obligations under the Credit Agreement are secured, subject to certain exceptions and limitations, by a lien on substantially all of the assets owned by us and each guarantor. The maturity date of the revolving credit facility and the term loan facility under the Credit Agreement is April 5, 2024. At our option, loans under the Credit Agreement will bear interest at a rate equal to adjusted LIBOR plus an applicable margin ranging from 1.25% to 2.00% or at an alternate base rate, which generally is defined as the highest of (i) the “Prime Rate” in the U.S. last quoted by The Wall Street Journal, (ii) 0.5% above the greater of the federal funds rate and the rate comprised of both overnight federal funds and overnight eurodollar borrowings and (iii) 1% above adjusted LIBOR for a one month interest period, plus in each case an applicable margin ranging from 0.125% to 1.00%, in each case subject to adjustments based on our consolidated total net leverage ratio. Overdue loans will bear interest at the rate otherwise applicable to such loans plus 2.00%. The Credit Agreement contains customary representations and warranties and covenants that, in each case, subject to certain exceptions, qualifications and thresholds, (a) place limitations on us regarding the incurrence of additional indebtedness, additional liens, fundamental changes, dispositions of property, investments and acquisitions, dividends and other restricted payments, transactions with affiliates, restrictive agreements, changes in lines of business and swap agreements, and (b) require us to comply with sanction laws and other laws and agreements, to deliver financial information and certain other information and give notice of certain events, to maintain their existence and good standing, to pay their other obligations, to permit the administrative agent and the lenders to inspect their books and property, to use the proceeds of the Credit Agreement only for certain permitted purposes and to provide collateral in the future. Subject to certain exceptions, we are required to maintain a maximum consolidated total net leverage ratio of 4.50 to 1.00. We are further required to maintain a minimum consolidated interest coverage ratio of 3.50 to 1.00. 4.625% Senior notes due 2027 In 2017, we issued $500.0 million of 4.625% Senior Notes due 2027 (the "2027 Notes"). We pay interest on the 2027 Notes semi-annually on May 15 and November 15, commencing on May 15, 2018, at a rate of 4.625% per year. The 2027 Notes mature on November 15, 2027 unless earlier redeemed by us at our option, as described below, or purchased by us at the holder’s option under specified circumstances following a Change of Control or Asset Sale (each as defined in the indenture related to the 2027 Notes), coupled with a downgrade in the ratings of the 2027 Notes, or upon our election to exercise our optional redemption rights, as described below. We incurred transaction fees of $7.9 million, including underwriters’ discounts and commissions, in connection with the offering of the 2027 Notes, which were recorded on the consolidated balance sheet as a reduction to long-term borrowings and are being amortized over the term of the 2027 Notes. We used the net proceeds from the offering to repay borrowings under our revolving credit facility. Our obligations under the 2027 Notes are fully and unconditionally guaranteed, jointly and severally, by each of our existing and future 100% owned domestic subsidiaries that is a guarantor or other obligor under the Credit Agreement and by certain of our other 100% owned domestic subsidiaries. At any time on or after November 15, 2022, we may, on one or more occasions, redeem some or all of the 2027 Notes at a redemption price of 102.313% of the principal amount of the 2027 Notes subject to redemption, declining, in annual increments of 0.771%, to 100% of the principal amount on November 15, 2025, plus accrued and unpaid interest. In addition, at any time prior to November 15, 2022, we may, on one or more occasions, redeem some or all of the 2027 Notes at a redemption price equal to 100% of the principal amount of the 2027 Notes redeemed, plus a “make-whole” premium and any accrued and unpaid interest. The “make-whole” premium is the greater of (a) 1.0% of the principal amount of the 2027 Notes subject to redemption or (b) the excess, if any, over the principal amount of the 2027 Notes of the present value, on the redemption date of the sum of (i) the November 15, 2022 optional redemption price plus (ii) all required interest payments on the 2027 Notes through November 15, 2022 (other than accrued and unpaid interest to the redemption date), generally computed using a discount rate equal to the yield to maturity of U.S. Treasury securities with a constant maturity for the period most nearly equal to the period from the redemption date to November 15, 2022 (unless the period is less than one year, in which case the weekly average yield on traded U.S. Treasury securities adjusted to a constant maturity of one year will be used), plus 50 basis points. In addition, at any time prior to November 15, 2020, we may, on one or more occasions, redeem up to 40% of the aggregate principal amount of the 2027 Notes, using the proceeds of specified types of Company equity offerings and subject to specified conditions, at a redemption price equal to 104.625% of the principal amount of the Notes redeemed, plus accrued and unpaid interest. The indenture relating to the 2027 Notes contains covenants that, among other things and subject to certain exceptions, limit or restrict our ability to create liens; merge, consolidate, sell or otherwise dispose of all or substantially all of our assets; or enter into sale leaseback transactions. 4.25% Senior Notes due 2028 In 2020, we issued $500.0 million of 4.25% Senior Notes due 2028 (the "2028 Notes"). We pay interest on the 2028 Notes semi-annually on June 1 and December 1, commencing on December 1, 2020, at a rate of 4.25% per year. The 2028 Notes mature on June 1, 2028 unless earlier redeemed at our option, as described below, or purchased at the holder’s option under specified circumstances following a Change of Control or Event of Default (each as defined in the indenture related to the 2028 Notes), coupled with a downgrade in the ratings of the 2028 Notes, or upon our election to exercise its optional redemption rights, as described below. We incurred transaction fees of $8.5 million, including underwriters’ discounts and commissions, in connection with the offering of the 2028 Notes, which were recorded on the consolidated balance sheet as a reduction to long-term borrowings and are being amortized over the term of the 2028 Notes. We used the net proceeds from the offering to repay borrowings under our revolving credit facility. Our obligations under the 2028 Notes are fully and unconditionally guaranteed, jointly and severally, by each of our existing and future 100% owned domestic subsidiaries that is a guarantor or other obligor under the Credit Agreement and by certain of our other 100% owned domestic subsidiaries. At any time on or after June 1, 2023, we may, on one or more occasions, redeem some or all of the 2028 Notes at a redemption price of 102.125% of the principal amount of the 2028 Notes subject to redemption, declining, in annual increments of 1.0625%, to 100% of the principal amount on June 1, 2025, plus accrued and unpaid interest. In addition, at any time prior to June 1, 2023, we may, on one or more occasions, redeem some or all of the 2028 Notes at a redemption price equal to 100% of the principal amount of the 2028 Notes redeemed, plus a “make-whole” premium and any accrued and unpaid interest. The “make-whole” premium is the greater of (a) 1.0% of the principal amount of the 2028 Notes subject to redemption or (b) the excess, if any, over the principal amount of the 2028 Notes, of the present value, on the redemption date, of the sum of (i) the June 1, 2023, optional redemption price plus (ii) all required interest payments on the 2028 Notes through June 1, 2023, (other than accrued and unpaid interest to the redemption date), generally computed using a discount rate equal to the yield to maturity of U.S. Treasury securities with a constant maturity for the period most nearly equal to the period from the redemption date to June 1, 2023 (unless the period is less than one year, in which case the weekly average yield on traded U.S. Treasury securities adjusted to a constant maturity of one year will be used), plus 50 basis points. In addition, at any time prior to June 1, 2023, we may, on one or more occasions, redeem up to 40% of the aggregate principal amount of the 2028 Notes, using the proceeds of specified types of our equity offerings and subject to specified conditions, at a redemption price equal to 104.25% of the principal amount of the Notes redeemed, plus accrued and unpaid interest. The indenture relating to the 2028 Notes contains covenants that, among other things, limit or restrict our ability, and the ability of our subsidiaries, to create liens; merge, consolidate, sell or otherwise dispose of all or substantially all of our assets; and enter into sale leaseback transactions. Securitization program We have an accounts receivable securitization facility under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of Teleflex. Accordingly, the assets of the SPE are not available to satisfy the obligations of Teleflex or any of its subsidiaries. The SPE sells undivided interests in those receivables to an asset backed commercial paper conduit for consideration of up to the maximum available capacity. On March 30, 2020, we amended our accounts receivable securitization facility to increase the maximum available capacity from $50 million to $75 million. This facility is utilized from time to time to provide increased flexibility in funding short term working capital requirements. The agreement governing the accounts receivable securitization facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this facility may give rise to the right of its counterparty to terminate this facility. As of December 31, 2021, we were in compliance with the covenants, and none of the termination events had occurred. As of December 31, 2021 and 2020, we had $75.0 million (the maximum amount available) of outstanding borrowings under our accounts receivable securitization facility. Fair value of long-term debt To determine the fair value of our debt for which quoted prices are not available, we use a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality and risk profile. Our implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of our debt as of December 31, 2021 and 2020, which is valued based on Level 2 inputs within the hierarchy used to measure fair value (see Note 12 to the consolidated financial statements for further information): December 31, 2021 December 31, 2020 Fair value of debt $ 1,893,518 $ 2,586,058 Debt Maturities As of December 31, 2021, the aggregate amounts of long-term debt, demand loans and debt under our securitization program that will mature during each of the next four years and thereafter were as follows: 2022 $ 110,000 2023 43,750 2024 709,750 2025 — 2026 and thereafter 1,000,000 Supplemental cash flow information Year Ended December 31, 2021 2020 2019 Cash interest paid $ 73,598 $ 79,533 $ 95,954

Financial instruments

Financial instruments	12 Months Ended
Financial instruments	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial instruments Foreign currency forward contracts We use derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flows hedges are used to manage foreign currency transaction exposure. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. We enter into the non-designated foreign currency forward contracts for periods consistent with the currency exposures, which generally approximate one month. For the years ended December 31, 2021 and 2020, we recognized losses related to non-designated foreign currency forward contracts of $8.9 million and $1.8 million, respectively. The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of December 31, 2021 and 2020 was $149.5 million and $129.5 million, respectively. The total notional amount for all open non-designated foreign currency forward contracts as of December 31, 2021 and 2020 was $161.2 million and $163.5 million, respectively. All open foreign currency forward contracts as of December 31, 2021 have durations of 12 months or less. Cross-currency interest rate swaps During 2019, we entered into cross-currency swap agreements with five different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $250 million at an annual interest rate of 4.8750% for €219.2 million at an annual interest rate of 2.4595%. The swap agreements are designed as net investment hedges and expire on March 4, 2024. During 2018, we entered into cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $500 million at an annual interest rate of 4.625% for €433.9 million at an annual interest rate of 1.942%. The swap agreements are designated as net investment hedges and expire on October 4, 2023. The swap agreements described above require an exchange of the notional amounts upon expiration or earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement. The cross-currency swaps are marked to market at each reporting date and any changes in fair value are recognized as a component of accumulated other comprehensive income (loss) ("AOCI") while the accrued interest is recognized in interest expense in the statement of operations. The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swap for the year ended December 31, 2021 and December 31, 2020: December 31, 2021 December 31, 2020 Foreign exchange gains $ 34,849 $ 37,312 Interest benefit 19,296 14,488 Balance sheet presentation The following table presents the locations in the consolidated balance sheets and fair value of derivative instruments as of December 31, 2021 and 2020: December 31, 2021 December 31, 2020 Asset derivatives: Designated foreign currency forward contracts $ 1,957 $ 1,691 Non-designated foreign currency forward contracts 56 61 Cross-currency interest rate swap 21,718 20,106 Prepaid expenses and other current assets 23,731 21,858 Cross-currency interest rate swap 9,560 — Other assets 9,560 — Total asset derivatives $ 33,291 $ 21,858 Liability derivatives: Designated foreign currency forward contracts $ 993 $ 1,504 Non-designated foreign currency forward contracts 147 366 Other current liabilities 1,140 1,870 Cross-currency interest rate swap — 34,125 Other liabilities — 34,125 Total liability derivatives $ 1,140 $ 35,995 See Note 13 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from AOCI to expense (income), net of tax. For the years ended December 31, 2021, 2020 and 2019, there was no ineffectiveness related to our hedging derivatives.

Fair value measurement

Fair value measurement	12 Months Ended
Fair value measurement	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement Fair value is the price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. Under GAAP, there is a three-level hierarchy of the inputs (i.e., assumptions that market participants would use in pricing an asset or liability) used to measure fair value. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the entire fair value measurement. The levels of inputs within the hierarchy used to measure fair value are as follows: Level 1 — inputs to the fair value measurement that are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 — inputs to the fair value measurement that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 — inputs to the fair value measurement that are unobservable inputs for the asset or liability. The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020: Basis of fair value measurement December 31, 2021 (Level 1) (Level 2) (Level 3) Investments in marketable securities $ 19,186 $ 19,186 $ — $ — Derivative assets 33,291 — 33,291 — Derivative liabilities 1,140 — 1,140 — Contingent consideration liabilities 9,814 — — 9,814 Basis of fair value measurement December 31, 2020 (Level 1) (Level 2) (Level 3) Investments in marketable securities $ 12,617 $ 12,617 $ — $ — Derivative assets 21,858 — 21,858 — Derivative liabilities 35,995 — 35,995 — Contingent consideration liabilities 36,633 — — 36,633 There were no transfers of financial assets or liabilities into or out of Level 3 within the fair value hierarchy during the years ended December 31, 2021 or 2020. Valuation Techniques Our financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices. Our financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts and cross-currency interest rate swap agreements. We use foreign currency forward contracts and cross-currency interest rate swap agreements to manage foreign currency transaction exposure as well as exposure to foreign currency denominated monetary assets and liabilities. We measure the fair value of the foreign currency forward and cross-currency swap agreements by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties. Our financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to our acquisitions. Contingent consideration Contingent consideration liabilities, which primarily consist of payment obligations that are contingent upon the achievement of revenue-based goals, but also can be based on other milestones such as regulatory approvals, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of payment and projected payment dates. The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration. Contingent Consideration Liability Valuation Technique Unobservable Input Range (Weighted average) Milestone-based payment Discounted cash flow Discount rate 1.9% - 2.2% (2.0%) Projected year of payment 2022 - 2023 Revenue-based Discounted cash flow Discount rate 1.7% - 10.0% (6.1%) Projected year of payment 2022 - 2029 The following table provides information regarding changes in our contingent consideration liabilities for the years ended December 31, 2021 and 2020: 2021 2020 Beginning balance – January 1 $ 36,633 $ 219,908 Payments (1) (31,678) (146,971) Revaluations and other adjustments 4,895 (36,714) Translation adjustment (36) 410 Ending balance – December 31 $ 9,814 $ 36,633 (1) Includes $17.4 million payment associated with a settlement reached with the shareholders from whom we acquired Essential Medical, Inc. See Note 17 for additional information related to the settlement.

Shareholders' equity

Shareholders' equity	12 Months Ended
Shareholders' equity	Dec. 31, 2021
Equity [Abstract]
Shareholders' equity	Shareholders' equity Our authorized capital is comprised of 200 million common shares, $1 par value, and 500,000 preference shares. No preference shares have been outstanding during the last three years. Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average shares outstanding: 2021 2020 2019 Basic 46,774 46,488 46,200 Dilutive effect of share based awards 653 799 890 Diluted 47,427 47,287 47,090 Weighted average shares that were antidilutive and therefore excluded from the calculation of diluted earnings per share were 0.1 million for the years ended December 31, 2021, 2020 and 2019. The following tables provides information relating to the changes in accumulated other comprehensive income (loss), net of tax, for each of the years ended December 31, 2021 and 2020: Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2019 $ 735 $ (138,810) $ (206,317) $ (344,392) Other comprehensive (loss) income before reclassifications (3,331) (17,032) 59,758 39,395 Amounts reclassified from accumulated other comprehensive income 2,114 5,585 — 7,699 Net current-year other comprehensive (loss) income (1,217) (11,447) 59,758 47,094 Balance at December 31, 2020 (482) (150,257) (146,559) (297,298) Other comprehensive income (loss) before reclassifications 351 6,192 (63,191) (56,648) Amounts reclassified from accumulated other comprehensive income 1,212 5,775 — 6,987 Net current-year other comprehensive (loss) income 1,563 11,967 (63,191) (49,661) Balance at December 31, 2021 $ 1,081 $ (138,290) $ (209,750) $ (346,959) The following table provides information relating to the losses (gains) recognized in the statements of income including the reclassifications of losses (gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the years ended December 31, 2021, 2020 and 2019: Year Ended December 31, 2021 2020 2019 Losses (gains) on designated foreign exchange forward contracts: Cost of goods sold $ 1,150 $ 2,354 $ (1,284) Total before tax 1,150 2,354 (1,284) Taxes expense (benefit) 62 (240) 150 Net of tax $ 1,212 $ 2,114 $ (1,134) Amortization of pension and other postretirement benefits items: Actuarial losses (1) $ 8,543 $ 7,253 $ 6,930 Prior-service credits (1) (1,012) 33 82 Total before tax 7,531 7,286 7,012 Tax benefit (1,756) (1,701) (1,631) Net of tax $ 5,775 $ 5,585 $ 5,381 Impact on income from continuing operations, net of tax $ 6,987 $ 7,699 $ 4,247 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 16 for additional information).

Stock compensation plans

Stock compensation plans	12 Months Ended
Stock compensation plans	Dec. 31, 2021
Share-based Payment Arrangement, Noncash Expense [Abstract]
Stock compensation plans	Stock compensation plans In May of 2014, our stockholders approved the Teleflex Incorporated 2014 Stock Incentive Plan (the "Plan"). The Plan provides for several different kinds of awards, including stock options, stock appreciation rights, stock awards and other stock-based awards to directors, officers and key employees. Under the Plan, we are authorized to issue up to 5.3 million shares of common stock, subject to adjustment in accordance with special share counting rules in the Plan. Options granted under the Plan have an exercise price equal to the closing price of the common stock on the date of the grant. In 2021, we granted, under the Plan, non-qualified options to purchase 108,686 shares of common stock and granted restricted stock units relating to 59,210 shares of common stock under the Plan. We also granted performance share units (“PSUs”), as described in the following paragraph. In 2018, we began granting PSUs to specified senior managers. The PSUs are designed to provide further incentive to our senior management with respect to the achievement of our long term financial objectives. The PSU component of the equity incentive program is designed to provide shares of our common stock to the holder based upon our achievement of certain financial performance criteria during a designated performance period of three years. The number of shares to be awarded under the PSUs granted are subject to modification based upon our total stockholder return relative to a designated group of public companies. Assuming target performance is achieved, a total of 16,903 shares of common stock would be issuable in respect of the PSUs granted and a maximum of 42,272 shares would be issuable in respect of such PSUs upon achievement of maximum performance levels. The following table summarizes the share-based compensation activity: 2021 2020 2019 Share-based compensation expense $ 22,937 $ 20,739 $ 26,940 Total income tax benefit recognized for share-based compensation arrangements 10,912 21,958 21,121 Net excess tax benefit 6,355 17,549 15,380 The unrecognized compensation expense for all awards granted in 2021 as of the grant date was $37.8 million, which will be recognized over the vesting period of the awards. As of December 31, 2021, 3,082,554 shares were available for future grants under the Plan. Option Awards The fair value of options granted in 2021, 2020 and 2019 was estimated at the date of grant using a Black-Scholes option pricing model. The following weighted-average assumptions were used: 2021 2020 2019 Risk-free interest rate 0.67 % 1.16 % 2.44 % Expected life of option 5.01 years 5.00 years 4.99 years Expected dividend yield 0.34 % 0.39 % 0.47 % Expected volatility 30.03 % 23.98 % 23.92 % The following table summarizes the option activity during 2021: Shares Subject to Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding, beginning of the year 1,157,315 $ 195.57 Granted 108,686 403.99 Exercised (125,143) 175.90 Forfeited or expired (32,859) 334.14 Outstanding, end of the year 1,107,999 214.13 5.11 $ 136,520 Exercisable, end of the year 908,854 $ 181.31 4.37 $ 135,036 The weighted average grant date fair value for options granted during 2021, 2020 and 2019 was $103.87, $74.60 and $68.22, respectively. The total intrinsic value of options exercised during 2021, 2020 and 2019 was $27.4 million, $77.9 million and $64.3 million, respectively. We recorded $8.8 million of expense related to options during 2021, which is included in cost of goods sold or selling, general and administrative expenses. As of December 31, 2021, the unamortized share-based compensation cost related to non-vested stock options, net of expected forfeitures, was $9.4 million, which is expected to be recognized over a weighted-average period of 1.47 years. Authorized but unissued shares of our common stock are issued upon exercises of options. Stock Awards The fair value of PSUs granted were determined using a Monte Carlo simulation valuation model. The grant date fair value for the 2021 awards was $419.25. The fair value for restricted stock units granted in 2021, 2020 and 2019 was estimated at the date of grant based on the market price for the underlying stock on the grant date discounted for the risk free interest rate and the present value of expected dividends over the vesting period. The following weighted-average assumptions were used: 2021 2020 2019 Risk-free interest rate 0.28 % 1.07 % 2.41 % Expected dividend yield 0.34 % 0.38 % 0.46 % The following table summarizes the non-vested restricted stock unit activity during 2021: Number of Non-Vested Shares Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding, beginning of the year 150,812 $ 293.10 Granted 59,210 398.59 Vested (50,098) 260.32 Forfeited (24,546) 334.38 Outstanding, end of the year 135,378 $ 343.89 1.2 $ 44,469 We issued 59,210, 52,464 and 69,799 of non-vested restricted stock units in 2021, 2020 and 2019, respectively, the majority of which provide for vesting as to all underlying shares on the third anniversary of the grant date. The weighted average grant-date fair value for non-vested restricted stock units granted during 2021, 2020 and 2019 was $398.59, $344.70 and $286.51, respectively.

Income taxes

Income taxes	12 Months Ended
Income taxes	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The following table summarizes the components of the provision for income taxes from continuing operations: 2021 2020 2019 Current: Federal $ 134,336 $ 11,148 $ 19,374 State 16,970 9,644 8,220 Non-U.S. 35,399 35,042 23,690 Deferred: Federal (85,272) (9,475) (2,041) State (16,933) (13,734) (28,277) Non-U.S. (10,151) (10,694) (143,044) $ 74,349 $ 21,931 $ (122,078) At December 31, 2021, the cumulative unremitted earnings of subsidiaries outside the U.S. that are considered non-permanently reinvested and for which taxes have been provided approximated $1.3 billion. At December 31, 2021, the cumulative unremitted earnings of subsidiaries outside the U.S. that are considered permanently reinvested approximated $1.0 billion. Earnings considered permanently reinvested are expected to be reinvested indefinitely and, as a result, no additional deferred tax liability has been recognized with regard to these earnings. It is not practical to determine the deferred income tax liability on these earnings if, in the future, they are remitted to the U.S. because the income tax liability to be incurred, if any, is dependent on circumstances existing when remittance occurs. The following table summarizes the U.S. and non-U.S. components of income from continuing operations before taxes: 2021 2020 2019 U.S. $ 209,231 $ 233,034 $ 89,021 Non-U.S. 350,237 124,698 250,882 $ 559,468 $ 357,732 $ 339,903 Reconciliations between the statutory federal income tax rate and the effective income tax rate are as follows: 2021 2020 2019 Federal statutory rate 21.0 % 21.0 % 21.0 % Tax effect of international items (6.0) (5.3) (11.3) Foreign merger - deferred taxes (1) — — (38.0) Excess tax benefits related to share-based compensation (1.1) (4.9) (4.5) State taxes, net of federal benefit 0.1 (0.3) (4.9) Uncertain tax contingencies (0.1) (0.5) — Contingent consideration 0.2 (2.2) 3.4 Intellectual property impairment charge — (1.2) — Research and development tax credit (0.8) (1.1) (1.1) Other, net — 0.6 (0.5) 13.3 % 6.1 % (35.9) % (1) During 2019, we recognized a discrete tax benefit of $129.0 million resulting from a non-U.S. legal entity restructuring that eliminated the requirement to provide for withholding taxes on the future repatriation of certain non-permanently reinvested earnings. The effective income tax rate for 2021 was 13.3% compared to 6.1% for 2020. The effective income tax rate for 2021 reflects tax expense associated with the Respiratory business divestiture. The effective tax rate for 2020 reflects non-taxable contingent consideration adjustments, recognized in connection with a decrease in the fair value of our contingent consideration liabilities. Additionally, the effective tax rates for both 2021 and 2020 reflect a net excess tax benefit related to share-based compensation and a tax benefit relating to the revaluation of state deferred tax assets and liabilities due to business integrations and other changes. We are routinely subject to examinations by various taxing authorities. In conjunction with these examinations and as a regular practice, we establish and adjust reserves with respect to its uncertain tax positions to address developments related to those positions. We realized a net benefit of $0.8 million, $1.7 million and $0.1 million in 2021, 2020 and 2019 respectively, as a result of reducing our reserves with respect to uncertain tax positions, principally due to the expiration of a number of applicable statutes of limitations. The following table summarizes significant components of our deferred tax assets and liabilities at December 31, 2021 and 2020: 2021 2020 Deferred tax assets: Tax loss and credit carryforwards $ 168,113 $ 180,782 Lease Liabilities 32,127 25,429 Pension 350 12,237 Reserves and accruals 64,421 72,931 Other 4,379 7,996 Less: valuation allowances (143,177) (155,008) Total deferred tax assets 126,213 144,367 Deferred tax liabilities: Property, plant and equipment 24,479 25,633 Intangibles — stock acquisitions (1) 352,139 476,150 Unremitted non-U.S. earnings 73,385 91,539 Lease Assets 32,127 25,429 Other 7,387 2,221 Total deferred tax liabilities 489,517 620,972 Net deferred tax liability $ (363,304) $ (476,605) (1) In December of 2021, we executed an intra-company transfer in which certain intellectual property rights held by several of our subsidiaries were contributed to a non-U.S. subsidiary. The transfer accelerated certain taxable income into the year ended December 31, 2021; however, the related current tax expense of $73.2 million, which is payable in 2022, was substantially offset by the reversal of existing deferred tax liabilities. Under the tax laws of various jurisdictions in which we operate, deductions or credits that cannot be fully utilized for tax purposes during the current year may be carried forward, subject to statutory limitations, to reduce taxable income or taxes payable in a future tax year. At December 31, 2021, the tax effect of such carryforwards approximated $168.1 million. Of this amount, $15.7 million has no expiration date, $19.2 million expires after 2021 but before the end of 2026 and $133.2 million expires after 2026. A portion of these carryforwards consists of tax losses and credits obtained by us as a result of acquisitions; the utilization of these carryforwards are subject to an annual limitation imposed by Section 382 of the Internal Revenue Code, which limits a company’s ability to deduct prior net operating losses following a more than 50 percent change in ownership. It is not expected that the Section 382 limitation will prevent us ultimately from utilizing the applicable loss carryforwards. The determination of state net operating loss carryforwards is dependent upon the U.S. subsidiaries’ taxable income or loss, the state’s proportion of each subsidiary's taxable net income and the application of state laws, which can change from year to year and impact the amount of such carryforward. The valuation allowance for deferred tax assets of $143.2 million and $155.0 million at December 31, 2021 and 2020, respectively, relates principally to the uncertainty of our ability to utilize certain deferred tax assets, primarily tax loss and credit carryforwards in various jurisdictions. The valuation allowance was calculated in accordance with applicable accounting standards, which require that a valuation allowance be established and maintained when it is “more likely than not” that all or a portion of deferred tax assets will not be realized. Uncertain Tax Positions : The following table is a reconciliation of the beginning and ending balances for liabilities associated with unrecognized tax benefits for the years ended December 31, 2021, 2020 and 2019: 2021 2020 2019 Balance at January 1 $ 7,230 $ 7,561 $ 8,106 Increase in unrecognized tax benefits related to prior years — 1,286 351 Decrease in unrecognized tax benefits related to prior years — — (201) Unrecognized tax benefits related to the current year — — 1,237 Reductions in unrecognized tax benefits due to lapse of applicable statute of limitations (956) (1,864) (1,881) Increase (decrease) in unrecognized tax benefits due to foreign currency translation (169) 247 (51) Balance at December 31 $ 6,105 $ 7,230 $ 7,561 The total liabilities associated with the unrecognized tax benefits that, if recognized, would impact the effective tax rate for continuing operations, were $3.8 million at December 31, 2021. We accrue interest and penalties associated with unrecognized tax benefits in income tax expense in the consolidated statements of income, and the corresponding liability is included in the consolidated balance sheets. The net interest expense (benefit) and penalties reflected in income from continuing operations for the year ended December 31, 2021 was $0.2 million and $(0.3) million, respectively; for the year ended December 31, 2020 was $0.2 million and $(0.5) million, respectively; and for the year ended December 31, 2019 was $0.2 million and $(0.1) million, respectively. The liabilities in the consolidated balance sheets for interest and penalties at December 31, 2021 were $0.8 million and $1.8 million, respectively, and at December 31, 2020 were $0.7 million and $2.1 million, respectively. The taxable years for which the applicable statute of limitations remains open by major tax jurisdictions are as follows: Beginning Ending U.S. 2018 2021 Canada 2017 2021 China 2016 2021 Czech Republic 2018 2021 France 2019 2021 Germany 2011 2021 India 2002 2021 Ireland 2017 2021 Italy 2016 2021 Malaysia 2017 2021 Singapore 2017 2021 We are routinely subject to income tax examinations by various taxing authorities. As of December 31, 2021, the most significant tax examinations in process were in Ireland and Germany. The date at which these examinations may be concluded and the ultimate outcome of the examinations are uncertain. As a result of the uncertain outcome of this ongoing examinations, future examinations or the expiration of statutes of limitation, it is reasonably possible that the related unrecognized tax benefits for tax positions taken could materially change from those recorded as liabilities at December 31, 2021. Due to the potential for resolution of certain examinations, and the expiration of various statutes of limitations, it is reasonably possible that our unrecognized tax benefits may change within the next year by a range of zero to $1.1 million. Supplemental cash flow information Year Ended December 31, 2021 2020 2019 Income taxes paid, net of refunds $ 108,609 $ 77,163 $ 73,632

Pension and other postretiremen

Pension and other postretirement benefits	12 Months Ended
Pension and other postretirement benefits	Dec. 31, 2021
Retirement Benefits [Abstract]
Pension and other postretirement benefits	Pension and other postretirement benefits We have a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. The defined benefit pension plans are noncontributory. The benefits under these plans are based primarily on years of service and employees’ pay near retirement. Our funding policy for U.S. plans is to contribute annually, at a minimum, amounts required by applicable laws and regulations. Obligations under non-U.S. plans are systematically provided for by depositing funds with trustees or by book reserves. As of December 31, 2021, no further benefits are being accrued under the U.S. defined benefit pension plans and the other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement. Teleflex and certain of our subsidiaries provide medical, dental and life insurance benefits to pensioners or their survivors. The associated plans are unfunded and approved claims are paid from our funds. The following table provides information regarding the components of the net benefit (income) expense of the pension and postretirement benefit plans for the years ended December 31, 2021, 2020 and 2019: Pension Other Benefits 2021 2020 2019 2021 2020 2019 Service cost $ 1,467 $ 1,416 $ 2,768 $ — $ — $ 9 Interest cost 9,272 12,827 16,000 418 902 1,391 Expected return on plan assets (30,726) (31,650) (27,426) — — — Net amortization and deferral 8,589 7,447 7,013 (1,058) (161) (1) Net benefit (income) expense $ (11,398) $ (9,960) $ (1,645) $ (640) $ 741 $ 1,399 Net benefit (income) expense is primarily included in selling, general and administrative expenses within the consolidated statements of income. The following table provides the weighted average assumptions for U.S. and foreign plans used in determining net benefit cost: Pension Other Benefits 2021 2020 2019 2021 2020 2019 Discount rate 2.5 % 3.2 % 4.3 % 2.3 % 3.1 % 4.2 % Rate of return 6.7 % 7.5 % 7.7 % Initial healthcare trend rate 6.8 % 7.0 % 7.4 % Ultimate healthcare trend rate 4.5 % 5.0 % 5.0 % The following table provides summarized information with respect to the pension and postretirement benefit plans, measured as of December 31, 2021 and 2020: Pension Other Benefits 2021 2020 2021 2020 Benefit obligation, beginning of year $ 501,347 $ 470,236 $ 31,921 $ 40,042 Service cost 1,467 1,416 — — Interest cost 9,272 12,827 418 902 Actuarial (gain) loss (13,567) 36,726 (2,288) 964 Currency translation (1,726) 2,273 — — Benefits paid (21,138) (21,092) (3,303) (5,448) Medicare Part D reimbursement — — 56 119 Plan amendments — 47 — (4,658) Administrative costs (981) (1,086) — — Projected benefit obligation, end of year 474,674 501,347 26,804 31,921 Fair value of plan assets, beginning of year 457,626 423,300 Actual return on plan assets 22,124 43,276 Contributions 12,159 12,490 Benefits paid (21,138) (21,092) Administrative costs (981) (1,086) Currency translation 3 738 Fair value of plan assets, end of year 469,793 457,626 Funded status, end of year $ (4,881) $ (43,721) $ (26,804) $ (31,921) The actuarial gain for pension for the year ended December 31, 2021 was primarily due to an increase in the discount rate used to measure the obligation, partially offset by a change in census data as well as the mortality assumptions. The actuarial loss for pension for the year ended December 31, 2020 was primarily due to a decrease in the discount rate used to measure the obligation, partially offset by a change in the mortality assumptions. The accumulated benefit obligations (ABO) and the projected benefit obligations (PBO) for plans with ABO and PBO in excess of plan assets were $456.0 million and $456.6 million, respectively, at December 31, 2021 and $481.0 million and $481.8 million respectively, at December 31, 2020. The fair value of plan assets for plans with PBO and ABO in excess of plan assets were $449.8 million and $434.3 million, respectively, at December 31, 2021 and December 31, 2020, respectively. The following table sets forth the amounts recognized in the consolidated balance sheet with respect to the pension and postretirement plans: Pension Other Benefits 2021 2020 2021 2020 Other assets $ 17,827 $ 3,703 $ — $ — Payroll and benefit-related liabilities (1,602) (1,721) (2,725) (3,125) Pension and postretirement benefit liabilities (21,106) (45,703) (24,079) (28,796) Accumulated other comprehensive loss (gain) 218,139 232,540 (2,847) (1,617) $ 213,258 $ 188,819 $ (29,651) $ (33,538) The following tables set forth the amounts recognized in accumulated other comprehensive income with respect to the plans: Pension Prior Service Cost Net (Gain) or Loss Deferred Taxes Accumulated Other Comprehensive Balance at December 31, 2019 $ 173 $ 213,816 $ (76,270) $ 137,719 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral (15) (7,432) 1,738 (5,709) Amounts arising during the period: Actuarial changes in benefit obligation — 25,100 (5,875) 19,225 Plan amendments 47 — (9) 38 Impact of currency translation — 851 (241) 610 Balance at December 31, 2020 205 232,335 (80,657) 151,883 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral (5) (8,584) 1,999 (6,590) Amounts arising during the period: Actuarial changes in benefit obligation — (4,965) 1,148 (3,817) Impact of currency translation — (847) 237 (610) Balance at December 31, 2021 $ 200 $ 217,939 $ (77,273) $ 140,866 Other Benefits Prior Service Cost Net (Gain) or Loss Deferred Taxes Accumulated Other Comprehensive Balance at December 31, 2019 $ 7 $ 1,909 $ (825) $ 1,091 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral (18) 179 (37) 124 Amounts arising during the period: Actuarial changes in benefit obligation — 964 (223) 741 Plan amendments (4,658) — 1,076 (3,582) Balance at December 31, 2020 (4,669) 3,052 (9) (1,626) Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral 1,017 41 (243) 815 Amounts arising during the period: Actuarial changes in benefit obligation — (2,288) 523 (1,765) Balance at December 31, 2021 $ (3,652) $ 805 $ 271 $ (2,576) The following table provides the weighted average assumptions for U.S. and foreign plans used in determining benefit obligations: Pension Other Benefits 2021 2020 2021 2020 Discount rate 2.8 % 2.5 % 2.7 % 2.3 % Rate of compensation increase 2.8 % 2.8 % Initial healthcare trend rate 6.0 % 6.4 % Ultimate healthcare trend rate 4.5 % 4.5 % The discount rate represents the interest rate used to determine the present value of future cash flows currently expected to be required to settle the pension and other benefit obligations. The weighted average discount rates for U.S. pension plans and other benefit plans of 2.95% and 2.69%, respectively, were established by comparing the projection of expected benefit payments to the AA Above Median yield curve as of December 31, 2021. The expected benefit payments are discounted by each corresponding discount rate on the yield curve. For payments beyond 30 years, we extend the curve assuming that the discount rate derived in year 30 is extended to the end of the plan’s payment expectations. Once the present value of the string of benefit payments is established, we determine the single rate on the yield curve that, when applied to all obligations of the plan, will exactly match the previously determined present value. As part of the evaluation of pension and other postretirement assumptions, we applied assumptions for mortality and healthcare cost trends that incorporate generational white and blue collar mortality trends. In determining its benefit obligations, we used generational tables that take into consideration increases in plan participant longevity. Our assumption for the expected return on plan assets is primarily based on the determination of an expected return for its current portfolio. This determination is made using assumptions for return and volatility of the portfolio. Asset class assumptions are set using a combination of empirical and forward-looking analysis. To the extent historical results have been affected by unsustainable trends or events, the effects of those trends are quantified and removed. We apply a variety of models for filtering historical data and isolating the fundamental characteristics of asset classes. These models provide empirical return estimates for each asset class, which are then reviewed and combined with a qualitative assessment of long term relationships between asset classes before a return estimate is finalized. The qualitative analysis is intended to provide an additional means for addressing the effect of unrealistic or unsustainable short-term valuations or trends, resulting in return levels and behavior we believe are more likely to prevail over long periods. Effective in 2022, we changed the expected return on plan assets of the U.S. pension plans from 7.00% to 5.80% due to modifications to the investment strategy in order to gradually reduce portfolio risk. The change had no impact on the results for the year ended December 31, 2021. The accumulated benefit obligation for all U.S. and foreign defined benefit pension plans was $474.1 million and $500.6 million for 2021 and 2020, respectively. All of the pension plans had accumulated benefit obligations in excess of their respective plan assets as of December 31, 2021 and 2020, with the exception of one foreign plan that had plan assets of $2.0 million and $3.7 million in excess of the accumulated benefit obligation as of December 31, 2021 and 2020, respectively. Our investment objective is to achieve an enhanced long-term rate of return on plan assets, subject to a prudent level of portfolio risk, for the purpose of enhancing the availability of benefits for participants. These investments are primarily comprised of equity and fixed income mutual funds. Our other investments are largely comprised of a hedge fund of funds and a structured credit fund. The equity funds are diversified in terms of domestic and international equity securities, as well as small, middle and large capitalization stocks. Our target allocation percentage is as follows: equity securities (26%) and fixed-income securities (74%). Equity funds are held for their expected return over inflation. Fixed-income funds are held for diversification relative to equities and as a partial hedge of interest rate risk with respect to plan liabilities. The other investments are held to further diversify assets within the plans and are designed to provide a mix of equity and bond like return with a bond like risk profile. The plans may also hold cash to meet liquidity requirements. Actual performance may not be consistent with the respective investment strategies. Investment risks and returns are measured and monitored on an ongoing basis through annual liability measurements and investment portfolio reviews to determine whether the asset allocation targets continue to represent an appropriate balance of expected risk and reward. The following table provides the fair values of the pension plan assets at December 31, 2021 by asset category: Fair Value Measurements Asset Category (a) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash $ 923 $ 923 — — Money market funds 6 6 — — Equity securities: Managed volatility (b) 57,252 57,252 — — U.S. small/mid-cap equity (c) 7,532 7,532 — — World equity (excluding U.S.) (d) 34,287 34,287 — — Fixed income securities: Intermediate duration fund (e) 101,363 101,363 — — Long duration bond fund (f) 171,919 171,919 — — Corporate bond fund (g) 7,607 7,607 — — Emerging markets debt fund (h) 7,605 7,605 — — Corporate, government and foreign bonds 50,599 50,599 — — Absolute return credit fund (i) 671 — $ 671 — Asset backed – home loans 208 — 208 — Other types of investments: Contract with insurance company (j) 19,130 — — $ 19,130 Other 3 — — 3 Total investments at fair value $ 459,105 $ 439,093 $ 879 $ 19,133 Investments measured at net asset value (k) 10,688 Total $ 469,793 The following table provides the fair values of the pension plan assets at December 31, 2020 by asset category: Fair Value Measurements Asset Category (a) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash $ 582 $ 582 — — Money market funds 12 12 — — Equity securities: Managed volatility (b) 85,974 85,974 — — U.S. small/mid-cap equity (c) 11,780 11,780 — — World equity (excluding U.S.) (d) 59,467 59,467 — — Common equity securities – Teleflex Incorporated 29,592 29,592 — — Fixed income securities: Intermediate duration fund (e) 63,376 63,376 — — Long duration bond fund (f) 98,996 98,996 — — Corporate bond fund (g) 13,469 13,469 — — Emerging markets debt fund (h) 11,412 11,412 — — Corporate, government and foreign bonds 35,582 35,582 — — Asset backed – home loans 261 — $ 261 — Other types of investments: Multi asset funds (l) 8,890 4,057 4,833 — Contract with insurance company (j) 10,485 — — $ 10,485 Other 4 — — 4 Total investments at fair value $ 429,882 $ 414,299 $ 5,094 $ 10,489 Investments measured at Net asset value (k) 27,744 Total $ 457,626 (a) Information on asset categories described in notes (b)-(l) is derived from prospectuses and other material provided by the respective funds comprising the respective asset categories. (b) This category comprises mutual funds that invest in securities of U.S. and non-U.S. companies of all capitalization ranges that exhibit relatively low volatility. (c) This category comprises a mutual fund that invests at least 80% of its net assets in equity securities of small and mid-sized companies. The fund invests in common stocks or exchange traded funds holding common stock of U.S. companies with market capitalizations in the range of companies in the Russell 2500 Index. (d) This category comprises a mutual fund that invests at least 80% of its net assets in equity securities of foreign companies. These securities may include common stocks, preferred stocks, warrants, exchange traded funds based on an international equity index, derivative instruments whose value is based on an international equity index and derivative instruments whose value is based on an underlying equity security or a basket of equity securities. The fund invests in securities of foreign issuers located in developed and emerging market countries. However, the fund will not invest more than 35% of its assets in the common stocks or other equity securities of issuers located in emerging market countries. (e) This category comprises a mutual fund that invests in instruments or derivatives having economic characteristics similar to fixed income securities. The fund invests in investment grade fixed income instruments, including U.S. and foreign corporate obligations, fixed income securities issued by sovereigns or agencies in both developed and emerging foreign markets, debt obligations issued by governments or other municipalities, and securities issued or guaranteed by the U.S. Government and its agencies. The fund will seek to maintain an effective average duration between three (f) This category comprises a mutual fund that invests in instruments or derivatives having economic characteristics similar to fixed income securities. The fund invests in investment grade fixed income instruments, including securities issued or guaranteed by the U.S. Government and its agencies and instrumentalities, corporate bonds, asset-backed securities, exchange traded funds, mortgage-backed securities and collateralized mortgage-backed securities. The fund invests primarily in long duration government and corporate fixed income securities, and uses derivative instruments, including interest rate swap agreements and Treasury futures contracts, for the purpose of managing the overall duration and yield curve exposure of the Fund’s portfolio of fixed income securities. (g) This category comprises funds that invest primarily in higher-yielding fixed income securities, including corporate bonds and debentures, convertible and preferred securities and zero coupon obligations. (h) This category comprises a mutual fund that invests at least 80% of its net assets in fixed income securities of emerging market issuers, primarily in U.S. dollar-denominated debt of foreign governments, government-related and corporate issuers in emerging market countries and entities organized to restructure the debt of those issuers. (i) This category comprises a mutual fund that invests primarily in investment grade bonds and similar fixed income and floating rate securities. (j) This category comprises the asset established out of an agreement to purchase a bulk-annuity policy from an insurer to fully cover the liabilities for members of the pension plan. The asset value is based on the fair value of the contract as determined by the insurance company using inputs that are not observable. (k) This category comprises pooled institutional investments, primarily collective investment trusts. These funds are not listed on an exchange or traded in an active market and these investments are valued using their net asset value, which is generally based on the underlying asset values of the pooled investments held in the trusts. This category comprises the following funds: • a fund that invests primarily in collateralized debt obligations and other structured credit vehicles and may include fixed income securities, loan participations, credit-linked notes, medium-term notes, pooled investment vehicles and derivative instruments. • a hedge fund that invests in various other hedge funds. • funds that invest in underlying funds that acquire, manage, and dispose of real estate properties, with a focus on properties in the U.S. and the UK markets. (l) This category comprises funds that may invest in equities, bonds, or derivatives. Our contributions to U.S. and foreign pension plans during 2022 are expected to be approximately $1.6 million. Contributions to postretirement healthcare plans during 2022 are expected to be approximately $2.7 million. The following table provides information about the expected benefit payments under its U.S. and foreign plans for each of the five succeeding years and the aggregate of the five years thereafter, net of the annual average Medicare Part D subsidy of approximately $0.1 million: Pension Other Benefits 2022 $ 22,732 $ 2,723 2023 22,859 2,630 2024 23,583 2,432 2025 23,976 2,348 2026 24,622 2,073 Years 2027 — 2031 127,007 7,388 We maintain a number of defined contribution savings plans covering eligible U.S. and non-U.S. employees. We partially match employee contributions. Costs related to these plans were $23.2 million, $21.7 million and $17.5 million for 2021, 2020 and 2019, respectively.

Commitments and contingent liab

Commitments and contingent liabilities	12 Months Ended
Commitments and contingent liabilities	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	Commitments and contingent liabilities Environmental: We are subject to contingencies as a result of environmental laws and regulations that in the future may require us to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by us or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require us to undertake certain investigative and remedial activities at sites where we conduct or once conducted operations or at sites where Company-generated waste was disposed. Remediation activities vary substantially in duration and cost from site to site. The nature of these activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At December 31, 2021 and 2020, we have recorded $2.0 million and $1.6 million, respectively, in accrued liabilities and $4.1 million and $5.2 million, respectively in other liabilities relating to these matters. Considerable uncertainty exists with respect to these liabilities, and if adverse changes in circumstances occur, potential liability may exceed the amount accrued as of December 31, 2021. The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 10-15 years. Legal matters: We are a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment, environmental and other matters. As of December 31, 2021 and 2020, we have recorded accrued liabilities of $0.2 million and $0.3 million, respectively, in connection with such contingencies, representing our best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. On February 17, 2021, representatives of the selling shareholders from whom we acquired Essential Medical, Inc. filed suit on behalf of such shareholders in the Court of Chancery of the State of Delaware alleging, among other things, that we breached the merger agreement relating to the acquisition in connection with activities relating to the achievement of revenue-based milestone goals under the agreement. The suit sought money damages in the amount of $66.9 million, plus interest. During the second quarter of 2021, the parties entered into a settlement agreement, pursuant to which we paid $17.4 million to the selling shareholders, the selling shareholders released us from the claims asserted in the lawsuit as well as any remaining obligations to make milestone payments and any other obligations relating to the merger agreement, and the lawsuit was dismissed with prejudice. As a result, we have no further potential liability related to this matter. In June 2020, we began producing documents and information in response to a Civil Investigative Demand (a “CID”) received in March 2020 by one of our subsidiaries, NeoTract, from the U.S. Department of Justice through the United States Attorney’s Office for the Northern District of Georgia (collectively, the “DOJ”). The CID relates to the DOJ’s investigation of a single NeoTract customer, requires the production of documents and information pertaining to communications with, and certain rebate programs offered to, that customer and pertains to communications and activities occurring both prior to our acquisition of NeoTract in October 2017 and thereafter. In July 2020, the DOJ advised us that it had opened an investigation under the civil False Claims Act, 31 U.S.C. §3729, with respect to NeoTract’s operations broadly in addition to the customer investigation. Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred. We maintain policies and procedures to promote compliance with the Anti-Kickback Statute, False Claims Acts and other applicable laws and regulations and intend to provide information sought by the government. We cannot at this time reasonably predict, however, the ultimate scope or outcome of this matter, including whether an investigation may raise other compliance issues of interest, including those beyond the scope described above or how any such issues might be resolved. We also cannot at this time reasonably estimate any potential liabilities or penalty, if any, that may arise from this matter, which could have a material adverse effect on our results of operations and financial condition. Other: As previously disclosed, we have been subject to an investigation by Chinese authorities related to a technical error regarding our country of origin designation for certain products we imported into China. Had the error not been made, we would have been obligated to make increased tariff payments in late 2018 through the first quarter of 2021. During the first quarter of 2021, we accrued the estimated increase in tariffs as well as related interest expense for the periods in question. In addition to the tariffs and related interest, the Chinese authorities may impose a penalty for the unpaid tariffs. During the third quarter of 2021, after receiving requests for payment of the increased tariff amounts from the Chinese authorities, we remitted payment for the increased tariffs and we believe this to be the final action required to close the case. We no longer consider payment of penalties or interest to be probable, so we reversed the $3.0 million of previously accrued penalties as well as the accrued interest. However, we have not received confirmation from the Chinese authorities that the case is closed and as a result, it remains possible that they may request payment for penalties and interest in the future. We believe the range of penalties could be between 30% and 200% of the increased tariff amount or between $3 million and $20 million.

Business segments and other inf

Business segments and other information	12 Months Ended
Business segments and other information	Dec. 31, 2021
Segment Reporting [Abstract]
Business segments and other information	Business segments and other information An operating segment is a component (a) that engages in business activities from which it may earn revenues and incur expenses, (b) whose operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance, and (c) for which discrete financial information is available. We do not evaluate our operating segments using discrete asset information. We have four reportable segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM (Original Equipment Manufacturer and Development Services). Our reportable segments, other than the OEM segment, design, manufacture and distribute medical devices primarily used in critical care and surgical applications and generally serve two end-markets: hospitals and healthcare providers, and home health. The products of these segments are most widely used in the acute care setting for a range of diagnostic and therapeutic procedures and in general and specialty surgical applications. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The following tables present our segment results for the years ended December 31, 2021, 2020 and 2019: Year Ended December 31, 2021 2020 2019 Americas $ 1,659,309 $ 1,465,035 $ 1,492,274 EMEA 606,807 584,859 588,043 Asia 297,766 267,016 294,328 OEM 245,681 220,246 220,717 Net revenues $ 2,809,563 $ 2,537,156 $ 2,595,362 Year Ended December 31, 2021 2020 2019 Americas $ 424,225 $ 401,391 $ 319,933 EMEA 94,865 81,348 94,424 Asia 84,648 51,238 73,090 OEM 56,210 44,852 57,994 Total segment operating profit (1) 659,948 578,829 545,441 Unallocated expenses (2) (31,853) (155,761) (118,187) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 628,095 $ 423,068 $ 427,254 (1) Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. For the years ended December 31, 2021, 2020 and 2019, corporate expenses were allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved. Commencing on January 1, 2022, all corporate expenses are allocated amongst the segments in proportion to the respective amounts of net revenues. The revised methodology does not impact period over period comparability because the change was immaterial. (2) Unallocated expenses primarily include manufacturing variances, except for fixed manufacturing cost absorption variances, restructuring and impairment charges and gain on sale of business and assets. Year Ended December 31, 2021 2020 2019 Americas $ 164,102 $ 151,111 $ 153,419 EMEA 45,022 47,012 44,328 Asia 11,140 13,594 14,072 OEM 17,098 15,535 6,550 Consolidated depreciation and amortization $ 237,362 $ 227,252 $ 218,369 Geographic data The following tables provide total net revenues and total net property, plant and equipment by geographic region for the years ended December 31, 2021, 2020 and 2019 and as of December 31, 2021 and 2020, respectively. Year Ended December 31, 2021 2020 2019 Net revenues (based on selling location): U.S. $ 1,769,488 $ 1,567,144 $ 1,606,248 Europe 665,000 646,577 652,069 Asia Pacific 263,022 230,267 241,278 All other 112,053 93,168 95,767 $ 2,809,563 $ 2,537,156 $ 2,595,362 As of December 31, Net property, plant and equipment: 2021 2020 U.S. $ 206,876 $ 234,186 Malaysia 72,541 71,760 Mexico 69,471 69,330 All other 94,870 98,636 $ 443,758 $ 473,912

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	Dec. 31, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS (Dollars in thousands) ALLOWANCE FOR DOUBTFUL ACCOUNTS Balance at Beginning of Year Additions Charged to Income Accounts Receivable Write-offs Translation and Other Balance at End of Year December 31, 2021 $ 12,875 $ 1,542 $ (3,001) $ (617) $ 10,799 December 31, 2020 $ 9,055 $ 3,798 $ (1,336) $ 1,358 $ 12,875 December 31, 2019 $ 9,348 $ 1,680 $ (1,739) $ (234) $ 9,055 DEFERRED TAX ASSET VALUATION ALLOWANCE Balance at Beginning of Year Additions Charged to Expense Reductions Credited to Expense Translation and Other Balance at End of Year December 31, 2021 $ 155,008 $ 7,770 $ (15,384) $ (4,217) $ 143,177 December 31, 2020 $ 119,233 $ 30,640 $ (59) $ 5,194 $ 155,008 December 31, 2019 $ 143,971 $ 31,564 $ (55,797) $ (505) $ 119,233

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
Summary of significant accounting policies (Policies)	Dec. 31, 2021
Accounting Policies [Abstract]
Consolidation	Consolidation: The consolidated financial statements include the accounts of Teleflex Incorporated and its subsidiaries (referred to herein as “we,” “us,” “our” and “Teleflex"). Intercompany transactions are eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and reflect management’s estimates and assumptions that affect the recorded amounts.
Use of estimates	Use of estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenues and expenses during the reporting period. Our estimates have considered the potential impacts stemming from the COVID-19 pandemic, which include increased uncertainty due to the difficulty in predicting the extent and duration of the pandemic. Accordingly, actual results could differ from those estimates.
Cash and cash equivalents	Cash and cash equivalents: All highly liquid debt instruments with an original maturity of three months or less are classified as cash equivalents. The carrying value of cash equivalents approximates the current market value.
Accounts receivable	Accounts receivable: Accounts receivable represent amounts due from customers related to the sale of products and provision of services. Our allowance for credit losses is maintained for trade accounts receivable based on the expected collectability of accounts receivable and losses expected to be incurred over the life of our receivables. Considerations to determine credit losses include our historical collection experience, the length of time an account is outstanding, the financial position of the customer, information provided by credit rating services, as well as the consideration of events or circumstances indicating historic collection rates may not be indicative of future collectability.
Inventories	Inventories: Inventories are valued at the lower of cost or net realizable value. The cost of our inventories is determined using the average cost method. Elements of cost in inventory include raw materials, direct labor, and manufacturing overhead. In estimating net realizable value, we evaluate inventory for excess and obsolete quantities based on estimated usage and sales, among other factors.
Property, plant and equipment	Property, plant and equipment: Property, plant and equipment are stated at cost, net of accumulated depreciation. Costs incurred to develop internal-use computer software during the application development stage generally are capitalized. Costs of enhancements to internal-use computer software are capitalized, provided that these enhancements result in additional functionality. Other additions and those improvements which increase the capacity or lengthen the useful lives of the assets are also capitalized. Composite useful lives for categories of property, plant and equipment, which are depreciated on a straight-line basis, are as follows: buildings — 30 years; machinery and equipment — 3 to 15 years; computer equipment and software — 3 to 10 years. Leasehold improvements are depreciated over the lesser of the useful lives of the leasehold improvements or the remaining lease term. Repairs and maintenance costs are expensed as incurred.
Goodwill and other intangible assets	Goodwill and other intangible assets: Goodwill and other indefinite-lived intangible assets are not amortized but are tested for impairment annually during the fourth quarter or more frequently if events or changes in circumstances indicate that an impairment may exist. Impairment losses, if any, are included in income from operations. The goodwill impairment test is applied to each of our reporting units. For purposes of this assessment, a reporting unit is an operating segment, or a business one level below an operating segment (also known as a component) if discrete financial information is prepared for that business and regularly reviewed by segment management. However, separate components are aggregated as a single reporting unit if they have similar economic characteristics. In performing the goodwill impairment test, we may assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Qualitative factors may include, but are not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for our products and services, regulatory and political developments, and entity specific factors such as strategies and financial performance. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of a reporting unit is less than its carrying value, we proceed to a quantitative impairment test, described below. Alternatively, we may elect to bypass the qualitative assessment and perform the quantitative impairment test. Under a quantitative impairment test, we compare the fair value of a reporting unit to its carrying value. If the reporting unit fair value exceeds the carrying value, there is no impairment. If the reporting unit carrying value exceeds the fair value, we recognize an impairment loss based on the amount the carrying value of the reporting unit exceeds its fair value. We did not record a goodwill impairment charge for the year ended December 31, 2021. Our intangible assets consist of customer relationships, intellectual property, distribution rights, in-process research and development ("IPR&D"), trade names and non-competition agreements. We define IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and is required be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or upon abandonment. Upon completion of the development project (generally when regulatory approval to market the product that utilizes the technology is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would be written off. We test our indefinite-lived intangible assets for impairment annually, or more frequently if events or changes in circumstances indicate that an impairment may have occurred. Similar to the goodwill impairment test process, we may elect to perform a qualitative assessment. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of the indefinite-lived intangible asset is greater than its carrying amount, the asset is not impaired. If we conclude it is more likely than not that the fair value of the indefinite-lived intangible asset is less than the carrying value, we then proceed to a quantitative impairment test, which consists of a comparison of the fair value of the intangible asset to its carrying amount. Intangible assets that do not have indefinite lives, consisting of intellectual property, customer relationships, distribution rights, certain trade names and non-competition agreements, are amortized over their estimated useful lives, which are as follows: intellectual property, 5 to 20 years; customer relationships, 8 to 27 years; distribution rights, 10 years; trade names, 5 to 30 years; non-competition agreements, 5 to 6 years. The weighted average remaining amortization period with respect to our intangible assets is approximately 15 years. We periodically evaluate the reasonableness of the useful lives of these assets.
Long-lived assets	Long-lived assets: We assess the remaining useful life and recoverability of long-lived assets whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The assessment is based on various analyses, including undiscounted cash flow and profitability projections that incorporate, as applicable, the impact of the asset on the existing business. Therefore, the evaluation involves significant management judgment. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.
Foreign currency translation	Foreign currency translation: Assets and liabilities of subsidiaries with non-United States dollar denominated functional currencies are translated into United States dollars at the rates of exchange at the balance sheet date; income and expenses are translated at the average rates of exchange prevailing during the year. The translation adjustments are reported as a component of accumulated other comprehensive loss.
Derivative financial instruments	Derivative financial instruments: We use derivative financial instruments primarily for purposes of hedging exposures to fluctuations in foreign currency exchange rates. All instruments are entered into for other than trading purposes. All derivatives are recognized on the balance sheet at fair value. Changes in the fair value of derivatives are recorded in the consolidated statement of comprehensive income as other comprehensive income (loss), if the instrument is designated as part of a hedge transaction. Gains or losses on derivative instruments reported in other comprehensive income (loss) are reclassified to the consolidated statement of income in the period in which earnings are affected by the underlying hedged item. Gains or losses on derivative instruments representing hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, if any, are recognized in the consolidated statement of income for the period in which such gains and losses occur. If the hedging relationship ceases to be highly effective or it becomes probable that an expected transaction will no longer occur, gains or losses on the derivative instrument are recorded in the consolidated statement of income for the period in which either such event occurs. For non-designated derivatives, gains and losses are reported as selling, general and administrative expenses in the consolidated statement of income. Cash flows from derivatives are recognized in the consolidated statements of cash flows in a manner consistent with recognition of the underlying transactions.
Share-based compensation	Share-based compensation: We estimate the fair value of share-based awards on the date of grant using an option pricing model. The value of the portion of the award that is ultimately expected to vest, which is derived, in part, following consideration of estimated forfeitures, is recognized as expense over the requisite service periods. Share-based compensation expense related to stock options is measured using a Black-Scholes option pricing model that takes into account subjective and complex assumptions with respect to the expected life of the options, volatility, risk-free interest rate and expected dividend yield. The expected life of options granted is derived from the vesting period of the award, as well as historical exercise behavior, and represents the period of time that options granted are expected to be outstanding. Expected volatility is based on a blend of historical volatility and implied volatility derived from publicly traded options to purchase our common stock, which we believe is more reflective of market conditions and a better indicator of expected volatility than would be the case if we only used historical volatility. The risk-free interest rate is the implied yield currently available on United States (or "U.S.") Treasury zero-coupon issues with a remaining term equal to the expected life of the option. Forfeitures are estimated at the time of grant based on management’s expectations regarding the extent to which awards ultimately will vest and are adjusted for actual forfeitures when they occur.
Income taxes	Income taxes: The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred tax assets and liabilities are recognized to reflect the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, and to reflect operating loss and tax credit carryforwards. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Provision has been made for income taxes on unremitted earnings of subsidiaries and affiliates, except to the extent that such earnings are deemed to be permanently reinvested. Significant judgment is required in determining income tax provisions and in evaluating tax positions. We establish additional provisions for income taxes when, despite the belief that tax positions are supportable, there remain certain positions that do not meet the minimum probability threshold, which is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority. In the normal course of business, we are examined by various federal, state and non-U.S. tax authorities. We regularly assess the potential outcomes of these examinations and any future examinations for the current or prior years in determining the adequacy of our provision for income taxes. Interest accrued with respect to unrecognized tax benefits and income tax related penalties are both included in taxes on income from continuing operations. We periodically assess the likelihood and amount of potential adjustments and adjust the income tax provision, the current tax liability and deferred taxes in the period in which the facts that give rise to an adjustment become known.
Pensions and other postretirement benefits	Pensions and other postretirement benefits: We provide a range of benefits to eligible employees and retired employees, including benefits available pursuant to pension and postretirement healthcare benefits plans. We record annual amounts relating to these plans based on calculations which include various actuarial assumptions such as discount rates, expected rates of return on plan assets, compensation increases, turnover rates and healthcare cost trend rates. We review our actuarial assumptions on an annual basis and make modifications to the assumptions based on current rates and trends when appropriate. The effect of the modifications is generally amortized over future periods.
Restructuring costs	Restructuring costs: We primarily recognize employee termination benefits when payment becomes probable and reasonably estimable because they are provided under an ongoing benefit arrangement and are based on existing plans, historical experience and negotiated settlements of prior plans. Termination benefits provided under one-time termination benefits arrangements, if any, are recognized upon communication to the employee. We recognize charges ratably over the future service period if the employee is required to render service until termination. Other restructuring costs may include facility closure, employee relocation, equipment relocation and outplacement costs and are recognized in the period they are incurred.
Contingent consideration related to business acquisitions	Contingent consideration related to business acquisitions: In connection with business acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified objectives such as receipt of regulatory approval, commercialization of a product or achievement of sales targets. As of the acquisition date, we record a contingent liability representing the estimated fair value of the contingent consideration that we expect to pay. We remeasure the fair value of our contingent consideration arrangements each reporting period and, based on new developments, record changes in fair value until either the contingent consideration obligation is satisfied through payment upon the achievement of, or the obligation no longer exists due to the failure to achieve, the specified objectives. The change in the fair value is recorded in selling, general and administrative expenses in the consolidated statement of income. A contingent consideration payment is classified as a financing activity in the consolidated statement of cash flows to the extent it was recorded as a liability as of the acquisition date. Any
Revenue recognition	Revenue recognition: We primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For the OEM segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which represented 89%, 9% and 2% of our consolidated net revenues, respectively, for the year ended December 31, 2021. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice. We have made the following revenue accounting policy elections and elected to use certain practical expedients: (1) we account for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) we do not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, we expect the period between the time when we transfer a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) we expense costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) we account for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service; (5) we classify shipping and handling costs within cost of goods sold; and (6) with respect to the OEM segment, we have applied the practical expedient to exclude disclosure of remaining performance obligations as the contracts typically have a term of one year or less. The amount of consideration we receive and revenue we recognize varies as a result of changes in customer sales incentives, including discounts and rebates, and returns offered to customers. The estimate of revenue is adjusted upon the earlier of the following events: (i) the most likely amount of consideration expected to be received changes or (ii) the consideration becomes fixed. Our policy is to accept returns only in cases in which the product is defective and covered under our standard warranty provisions. When we give customers the right to return products, we estimate the expected returns based on an analysis of historical experience. The liability for returns and allowances was $15.2 million and $14.6 million as of December 31, 2021 and 2020, respectively. In estimating customer rebates, we consider the lag time between the point of sale and the payment of the customer’s rebate claim, customer-specific trend analyses, contractual commitments, including stated rebate rates, historical experience with respect to specific customers (as we have a history of providing similar rebates on similar products to similar customers) and other relevant information. The reserve for customer incentive programs, including customer rebates, was $26.4 million and $28.5 million at December 31, 2021 and 2020, respectively. We expect the amounts subject to the reserve as of December 31, 2021 to be paid within 90 days subsequent to period-end.
Leases	Leases: On January 1, 2019 we adopted an amendment to the guidance on leases using a modified retrospective transition approach. We have made an accounting policy election not to apply the lease accounting recognition provisions to short term leases (leases with a lease term of 12 months or less that do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise); instead, we will recognize the lease payments for short term leases on a straight-line basis over the lease term. We have made, as a practical expedient, an accounting policy election to not separate lease and non-lease components and instead will account for each separate lease component and the non-lease components associated with that lease component as a single lease component.
Recently issued accounting standards	Recently issued accounting standards In December 2019, the FASB issued new guidance that simplifies various aspects of accounting for income taxes including those related to the step-up in the tax basis of goodwill, intraperiod tax allocations and the interim period effects of changes in tax laws or rates. The modifications under the new guidance were applied on a prospective basis effective January 1, 2021. The adoption of the new guidance did not have a material effect on the condensed consolidated financial statements.From time to time, new accounting guidance issued by the FASB or other standard setting bodies is adopted as of the specified effective date or, when permitted by the guidance and as determined by us, as of an earlier date. We have assessed recently issued guidance that is not yet effective, except as noted above, and believe the new guidance that we have assessed will not have a material impact on our results of operations, cash flows or financial position.

Net revenues (Tables)

Net revenues (Tables)	12 Months Ended
Net revenues (Tables)	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table disaggregates revenue by global product category for the year ended December 31, 2021, 2020 and 2019. Year Ended December 31 2021 2020 2019 Vascular access $ 700,240 $ 657,703 $ 600,874 Anesthesia 380,140 302,293 338,413 Interventional 427,500 382,435 427,563 Surgical 377,756 317,200 370,074 Interventional urology 341,661 290,022 290,449 OEM 245,681 220,246 220,717 Other (1) 336,585 367,257 347,272 Net revenues (2) $ 2,809,563 $ 2,537,156 $ 2,595,362 (1) Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products). Certain product lines within the respiratory product category were sold during 2021. See Note 4 for additional information related to the Respiratory business divestiture. (2) The product categories listed above are presented on a global basis, while each of our reportable segments other than the OEM reportable segment are defined based on the geographic location of its operations; the OEM reportable segment operates globally. Each of the geographically based reportable segments include net revenues from each of the non-OEM product categories listed above.

Acquisitions and Divestitures (

Acquisitions and Divestitures (Tables)	12 Months Ended
Acquisitions and Divestitures (Tables)	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Operating Results of Operations Treated as Discontinued Operations	The following assets and liabilities were sold as part of the initial phase of the Respiratory business divestiture: Assets Inventories $ 26,830 Current assets 26,830 Property, plant and equipment, net 17,006 Intangible assets, net 41,583 Goodwill 35,745 Operating lease assets 1,053 Other assets 94 Noncurrent assets 95,481 Total assets $ 122,311 Liabilities Other current liabilities $ 535 Noncurrent operating lease liabilities 568 Liabilities $ 1,103

Restructuring and impairment ch

Restructuring and impairment charges (Tables)	12 Months Ended
Restructuring and impairment charges (Tables)	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Summary of Current Cost Estimates by Major Type of Cost	The following table provides a summary of our cost estimates by major type of expense associated with the Respiratory divestiture plan: Total estimated amount expected to be incurred Program expense estimates: (Dollars in millions) Restructuring charges (1) $5 million to $8 million Restructuring related charges (2) $19 million to $22 million Total restructuring and restructuring related charges $24 million to $30 million (1) Substantially all of the charges consist of employee termination benefit costs. (2) Consist of charges that are directly related to the Respiratory divestiture plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold. 2019 Footprint realignment plan 2018 Footprint realignment plan 2014 Footprint realignment plan Program expense estimates: (Dollars in millions) Termination benefits $14 to $15 $60 to $65 $13 to $13 Other costs (1) 2 to 2 3 to 4 1 to 2 Restructuring charges 16 to 17 63 to 69 14 to 15 Restructuring related charges (2) 38 to 43 47 to 59 39 to 40 Total restructuring and restructuring related charges $54 to $60 $110 to $128 $53 to $55 Other program estimates: Expected cash outlays $48 to $54 $99 to $122 $43 to $46 Expected capital expenditures $31 to $33 $15 to $16 $26 to $27 Other program information: Period initiated February 2019 May 2018 April 2014 Estimated period of substantial completion 2022 2022 2022 Aggregate restructuring charges $15.6 $62.5 $13.8 Restructuring related charges incurred: For year ended December 31, 2021 $13.0 $10.7 $2.6 Aggregate restructuring related charges $34.1 $27.4 $38.6 (1) Includes facility closure, employee relocation, equipment relocation and outplacement costs.
Schedule of Restructuring Reserve	The following table summarizes the restructuring reserve activity related to our Respiratory divestiture plan, as well as the 2019, 2018 and 2014 Footprint realignment plans: Respiratory divestiture plan 2019 Footprint realignment plan 2018 Footprint realignment plan 2014 Footprint realignment plan Balance at December 31, 2019 (1) $ — $ 11,870 $ 44,274 $ 3,669 Subsequent accruals — 1,542 5,948 606 Cash payments — (5,532) (4,281) (682) Foreign currency translation and other — 174 4,140 — Balance at December 31, 2020 (1) — 8,054 50,081 3,593 Subsequent accruals 2,694 253 2,476 262 Cash payments (7) (4,982) (4,813) (947) Foreign currency translation and other (86) (19) (3,679) — Balance at December 31, 2021 (1) $ 2,601 $ 3,306 $ 44,065 $ 2,908 (1) The restructuring reserves as of December 31, 2021 , 2020 and 2019 consisted mainly of accruals related to termination benefits. Other costs (facility closure, employee relocation, equipment relocation and outplacement costs) were expensed and paid in the same period.
Restructuring and Other Impairment Charges	The restructuring and impairment charges recognized for the years ended December 31, 2021, 2020, and 2019 consisted of the following: 2021 Termination benefits Other Costs (1) Total Respiratory divestiture plan $ 2,687 $ 7 $ 2,694 2021 Restructuring plan 7,280 77 7,357 2019 Footprint realignment plan (111) 364 253 2018 Footprint realignment plan 2,335 141 2,476 Other restructuring programs (2) (429) 2,648 2,219 Total restructuring charges 11,762 3,237 14,999 Asset impairment charges — 6,739 6,739 Total restructuring and impairment charges $ 11,762 $ 9,976 $ 21,738 2020 Termination benefits Other Costs (1) Total 2020 Workforce reduction plan $ 8,494 $ 353 $ 8,847 2019 Footprint realignment plan 647 895 1,542 2018 Footprint realignment plan 5,565 383 5,948 Other restructuring programs (3) (72) 838 766 Total restructuring charges 14,634 2,469 17,103 Asset impairment charges — 21,388 21,388 Total restructuring and impairment charges $ 14,634 $ 23,857 $ 38,491 2019 Termination benefits Other Costs (1) Total 2019 Footprint realignment plan $ 13,683 $ 70 $ 13,753 2018 Footprint realignment plan (1,787) 848 (939) Other restructuring programs (4) 787 1,638 2,425 Total restructuring charges 12,683 2,556 15,239 Asset impairment charges — 6,966 6,966 Total restructuring and impairment charges $ 12,683 $ 9,522 $ 22,205 (1) Includes facility closure, contract termination and other exit costs. (2) Includes the 2020 Workforce reduction plan, a program initiated in the third quarter of 2019 and the 2014 Footprint realignment plan. (3) Includes activity primarily related to the 2016 and 2014 Footprint realignment plans. (4) Includes the 2020 Workforce reduction plan, the 2017 Vascular Solutions integration program as well as the 2016 and 2014 Footprint realignment plans.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories at December 31, 2021 and 2020 consist of the following: 2021 2020 Raw materials $ 146,433 $ 132,370 Work-in-process 81,503 75,874 Finished goods 249,707 304,952 Inventories $ 477,643 $ 513,196

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
Property, plant and equipment (Tables)	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Major Classes of Property, Plant and Equipment at Cost	The major classes of property, plant and equipment, at cost, at December 31, 2021 and 2020 were as follows: 2021 2020 Land, buildings and leasehold improvements $ 285,305 $ 272,637 Machinery and equipment 475,040 496,664 Computer equipment and software 191,605 172,913 Construction in progress 49,782 84,336 1,001,732 1,026,550 Less: Accumulated depreciation (557,974) (552,638) Property, plant and equipment, net $ 443,758 $ 473,912

Goodwill and other intangible_2

Goodwill and other intangible assets (Tables)	12 Months Ended
Goodwill and other intangible assets (Tables)	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill, by Reporting Segment	Changes in the carrying amount of goodwill, by reportable operating segment, for the years ended December 31, 2021 and 2020 were as follows: Americas EMEA Asia OEM Total Balance as of December 31, 2019 Goodwill $ 1,883,053 $ 475,772 $ 213,725 $ 4,883 $ 2,577,433 Accumulated impairment losses (332,128) — — — (332,128) 1,550,925 475,772 213,725 4,883 2,245,305 Goodwill related to acquisitions 149,877 22,364 15,698 107,127 295,066 Translation and other adjustments (520) 38,092 8,023 — 45,595 Balance as of December 31, 2020 1,700,282 536,228 237,446 112,010 2,585,966 Goodwill disposed (21,802) (7,537) (6,406) — (35,745) Goodwill related to acquisitions (1,560) (232) (163) — (1,955) Translation and other adjustments (696) (36,310) (7,058) — (44,064) Balance as of December 31, 2021 $ 1,676,224 $ 492,149 $ 223,819 $ 112,010 $ 2,504,202
Components of Intangible Assets	Intangible assets at December 31, 2021 and 2020 consisted of the following: Gross Carrying Amount Accumulated Amortization 2021 2020 2021 2020 Customer relationships $ 1,328,611 $ 1,377,943 $ (441,059) $ (425,692) In-process research and development 28,158 29,627 — — Intellectual property 1,440,643 1,458,924 (560,740) (479,612) Distribution rights 23,434 23,866 (20,630) (20,280) Trade names 549,269 619,847 (59,249) (65,955) Non-compete agreements 22,783 24,592 (22,153) (23,514) $ 3,392,898 $ 3,534,799 $ (1,103,831) $ (1,015,053)
Estimated Annual Amortization Expense	Amortization expense related to intangible assets was $165.6 million, $158.7 million, and $150.0 million for the years ended December 31, 2021, 2020 and 2019, respectively. The estimated annual amortization expense for each of the five succeeding years is as follows: 2022 $ 160,600 2023 154,800 2024 153,000 2025 151,800 2026 148,800

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2021
Leases [Abstract]
Schedule of Lessee, Operating Lease, Liability, Maturity	Maturities of lease liabilities December 31, 2021 2022 $ 26,682 2023 22,790 2024 19,279 2025 14,789 2026 15,307 2027 and thereafter 61,950 Total lease payments 160,797 Less: interest (22,634) Present value of lease liabilities $ 138,163
Supplemental Information, Lessee, Operating Lease	Supplemental information December 31, 2021 December 31, 2020 Total lease liabilities (1) $ 138,163 $ 108,743 Cash paid for amounts included in the measurement of lease liabilities within operating cash flows $ 29,199 $ 28,276 Right of use assets obtained in exchange for operating lease obligations $ 55,290 $ 8,904 Weighted average remaining lease term 7.9 years 6.7 years Weighted average discount rate 3.7 % 4.0 % (1) The current portion of the operating lease liability is included in other current liabilities .

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
Borrowings (Tables)	Dec. 31, 2021
Debt Disclosure [Abstract]
Components of Long-Term Debt	Our borrowings at December 31, 2021 and 2020 were as follows: 2021 2020 Senior Credit Facility: Revolving credit facility, at a rate of 1.48% at December 31, 2021, and 1.66% at December 31, 2020, due 2024 $ 141,000 $ 350,000 Term loan facility, at a rate of 1.48% at December 31, 2021 and 1.65% at December 31 2020, due 2024 647,500 673,000 4.875% Senior Notes due 2026 — 400,000 4.625% Senior Notes due 2027 500,000 500,000 4.25% Senior Notes due 2028 500,000 500,000 Securitization program, at a rate of 1.00% at December 31, 2021 and 1.24% at December 31, 2020 75,000 75,000 1,863,500 2,498,000 Less: Unamortized debt issuance costs (13,398) (19,612) 1,850,102 2,478,388 Current portion of borrowings (110,000) (100,500) Long-term borrowings $ 1,740,102 $ 2,377,888
Fair Value of Debt	The following table provides the fair value of our debt as of December 31, 2021 and 2020, which is valued based on Level 2 inputs within the hierarchy used to measure fair value (see Note 12 to the consolidated financial statements for further information): December 31, 2021 December 31, 2020 Fair value of debt $ 1,893,518 $ 2,586,058
Aggregate Amounts of Long-Term Debt	Debt Maturities As of December 31, 2021, the aggregate amounts of long-term debt, demand loans and debt under our securitization program that will mature during each of the next four years and thereafter were as follows: 2022 $ 110,000 2023 43,750 2024 709,750 2025 — 2026 and thereafter 1,000,000
Schedule of Cash Flow, Supplemental Disclosures, Debt	Supplemental cash flow information Year Ended December 31, 2021 2020 2019 Cash interest paid $ 73,598 $ 79,533 $ 95,954

Financial instruments (Tables)

Financial instruments (Tables)	12 Months Ended
Financial instruments (Tables)	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The following table presents the locations in the consolidated balance sheets and fair value of derivative instruments as of December 31, 2021 and 2020: December 31, 2021 December 31, 2020 Asset derivatives: Designated foreign currency forward contracts $ 1,957 $ 1,691 Non-designated foreign currency forward contracts 56 61 Cross-currency interest rate swap 21,718 20,106 Prepaid expenses and other current assets 23,731 21,858 Cross-currency interest rate swap 9,560 — Other assets 9,560 — Total asset derivatives $ 33,291 $ 21,858 Liability derivatives: Designated foreign currency forward contracts $ 993 $ 1,504 Non-designated foreign currency forward contracts 147 366 Other current liabilities 1,140 1,870 Cross-currency interest rate swap — 34,125 Other liabilities — 34,125 Total liability derivatives $ 1,140 $ 35,995
Schedule of foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense	The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swap for the year ended December 31, 2021 and December 31, 2020: December 31, 2021 December 31, 2020 Foreign exchange gains $ 34,849 $ 37,312 Interest benefit 19,296 14,488

Fair value measurement (Tables)

Fair value measurement (Tables)	12 Months Ended
Fair value measurement (Tables)	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020: Basis of fair value measurement December 31, 2021 (Level 1) (Level 2) (Level 3) Investments in marketable securities $ 19,186 $ 19,186 $ — $ — Derivative assets 33,291 — 33,291 — Derivative liabilities 1,140 — 1,140 — Contingent consideration liabilities 9,814 — — 9,814 Basis of fair value measurement December 31, 2020 (Level 1) (Level 2) (Level 3) Investments in marketable securities $ 12,617 $ 12,617 $ — $ — Derivative assets 21,858 — 21,858 — Derivative liabilities 35,995 — 35,995 — Contingent consideration liabilities 36,633 — — 36,633 There were no transfers of financial assets or liabilities into or out of Level 3 within the fair value hierarchy during the years ended December 31, 2021 or 2020.
Schedule of Valuation Techniques	The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration. Contingent Consideration Liability Valuation Technique Unobservable Input Range (Weighted average) Milestone-based payment Discounted cash flow Discount rate 1.9% - 2.2% (2.0%) Projected year of payment 2022 - 2023 Revenue-based Discounted cash flow Discount rate 1.7% - 10.0% (6.1%) Projected year of payment 2022 - 2029
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	The following table provides information regarding changes in our contingent consideration liabilities for the years ended December 31, 2021 and 2020: 2021 2020 Beginning balance – January 1 $ 36,633 $ 219,908 Payments (1) (31,678) (146,971) Revaluations and other adjustments 4,895 (36,714) Translation adjustment (36) 410 Ending balance – December 31 $ 9,814 $ 36,633 (1) Includes $17.4 million payment associated with a settlement reached with the shareholders from whom we acquired Essential Medical, Inc. See Note 17 for additional information related to the settlement.

Shareholders' equity (Tables)

Shareholders' equity (Tables)	12 Months Ended
Shareholders' equity (Tables)	Dec. 31, 2021
Equity [Abstract]
Schedule of Weighted Average Number of Shares	The following table provides a reconciliation of basic to diluted weighted average shares outstanding: 2021 2020 2019 Basic 46,774 46,488 46,200 Dilutive effect of share based awards 653 799 890 Diluted 47,427 47,287 47,090
Schedule of Accumulated Other Comprehensive Income (Loss)	The following tables provides information relating to the changes in accumulated other comprehensive income (loss), net of tax, for each of the years ended December 31, 2021 and 2020: Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2019 $ 735 $ (138,810) $ (206,317) $ (344,392) Other comprehensive (loss) income before reclassifications (3,331) (17,032) 59,758 39,395 Amounts reclassified from accumulated other comprehensive income 2,114 5,585 — 7,699 Net current-year other comprehensive (loss) income (1,217) (11,447) 59,758 47,094 Balance at December 31, 2020 (482) (150,257) (146,559) (297,298) Other comprehensive income (loss) before reclassifications 351 6,192 (63,191) (56,648) Amounts reclassified from accumulated other comprehensive income 1,212 5,775 — 6,987 Net current-year other comprehensive (loss) income 1,563 11,967 (63,191) (49,661) Balance at December 31, 2021 $ 1,081 $ (138,290) $ (209,750) $ (346,959)
Reclassification out of Accumulated Other Comprehensive Income	The following table provides information relating to the losses (gains) recognized in the statements of income including the reclassifications of losses (gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the years ended December 31, 2021, 2020 and 2019: Year Ended December 31, 2021 2020 2019 Losses (gains) on designated foreign exchange forward contracts: Cost of goods sold $ 1,150 $ 2,354 $ (1,284) Total before tax 1,150 2,354 (1,284) Taxes expense (benefit) 62 (240) 150 Net of tax $ 1,212 $ 2,114 $ (1,134) Amortization of pension and other postretirement benefits items: Actuarial losses (1) $ 8,543 $ 7,253 $ 6,930 Prior-service credits (1) (1,012) 33 82 Total before tax 7,531 7,286 7,012 Tax benefit (1,756) (1,701) (1,631) Net of tax $ 5,775 $ 5,585 $ 5,381 Impact on income from continuing operations, net of tax $ 6,987 $ 7,699 $ 4,247 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 16 for additional information).

Stock compensation plans (Table

Stock compensation plans (Tables)	12 Months Ended
Stock compensation plans (Tables)	Dec. 31, 2021
Share-based Payment Arrangement, Noncash Expense [Abstract]
Summary of Share-based Compensation Activity	The following table summarizes the share-based compensation activity: 2021 2020 2019 Share-based compensation expense $ 22,937 $ 20,739 $ 26,940 Total income tax benefit recognized for share-based compensation arrangements 10,912 21,958 21,121 Net excess tax benefit 6,355 17,549 15,380
Weighted-Average Assumptions used to Estimate Fair Value of Options Granted	The fair value of options granted in 2021, 2020 and 2019 was estimated at the date of grant using a Black-Scholes option pricing model. The following weighted-average assumptions were used: 2021 2020 2019 Risk-free interest rate 0.67 % 1.16 % 2.44 % Expected life of option 5.01 years 5.00 years 4.99 years Expected dividend yield 0.34 % 0.39 % 0.47 % Expected volatility 30.03 % 23.98 % 23.92 %
Summary of Stock Option Activity	The following table summarizes the option activity during 2021: Shares Subject to Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding, beginning of the year 1,157,315 $ 195.57 Granted 108,686 403.99 Exercised (125,143) 175.90 Forfeited or expired (32,859) 334.14 Outstanding, end of the year 1,107,999 214.13 5.11 $ 136,520 Exercisable, end of the year 908,854 $ 181.31 4.37 $ 135,036
Weighted-Average Assumptions used to Estimate Fair Value of Non-Vested Shares Granted	The following weighted-average assumptions were used: 2021 2020 2019 Risk-free interest rate 0.28 % 1.07 % 2.41 % Expected dividend yield 0.34 % 0.38 % 0.46 %
Summary of Non-Vested Restricted Stock Unit Activity	The following table summarizes the non-vested restricted stock unit activity during 2021: Number of Non-Vested Shares Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding, beginning of the year 150,812 $ 293.10 Granted 59,210 398.59 Vested (50,098) 260.32 Forfeited (24,546) 334.38 Outstanding, end of the year 135,378 $ 343.89 1.2 $ 44,469

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
Income taxes (Tables)	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Components of Provision for Income Taxes from Continuing Operations	The following table summarizes the components of the provision for income taxes from continuing operations: 2021 2020 2019 Current: Federal $ 134,336 $ 11,148 $ 19,374 State 16,970 9,644 8,220 Non-U.S. 35,399 35,042 23,690 Deferred: Federal (85,272) (9,475) (2,041) State (16,933) (13,734) (28,277) Non-U.S. (10,151) (10,694) (143,044) $ 74,349 $ 21,931 $ (122,078)
Summaries of U.S. and Non-U.S. Components of Income from Continuing Operations Before Taxes	The following table summarizes the U.S. and non-U.S. components of income from continuing operations before taxes: 2021 2020 2019 U.S. $ 209,231 $ 233,034 $ 89,021 Non-U.S. 350,237 124,698 250,882 $ 559,468 $ 357,732 $ 339,903
Reconciliations Between Statutory Federal Income Tax Rate and Effective Income Tax Rate	Reconciliations between the statutory federal income tax rate and the effective income tax rate are as follows: 2021 2020 2019 Federal statutory rate 21.0 % 21.0 % 21.0 % Tax effect of international items (6.0) (5.3) (11.3) Foreign merger - deferred taxes (1) — — (38.0) Excess tax benefits related to share-based compensation (1.1) (4.9) (4.5) State taxes, net of federal benefit 0.1 (0.3) (4.9) Uncertain tax contingencies (0.1) (0.5) — Contingent consideration 0.2 (2.2) 3.4 Intellectual property impairment charge — (1.2) — Research and development tax credit (0.8) (1.1) (1.1) Other, net — 0.6 (0.5) 13.3 % 6.1 % (35.9) % (1) During 2019, we recognized a discrete tax benefit of $129.0 million resulting from a non-U.S. legal entity restructuring that eliminated the requirement to provide for withholding taxes on the future repatriation of certain non-permanently reinvested earnings.
Deferred Tax Assets and Liabilities	The following table summarizes significant components of our deferred tax assets and liabilities at December 31, 2021 and 2020: 2021 2020 Deferred tax assets: Tax loss and credit carryforwards $ 168,113 $ 180,782 Lease Liabilities 32,127 25,429 Pension 350 12,237 Reserves and accruals 64,421 72,931 Other 4,379 7,996 Less: valuation allowances (143,177) (155,008) Total deferred tax assets 126,213 144,367 Deferred tax liabilities: Property, plant and equipment 24,479 25,633 Intangibles — stock acquisitions (1) 352,139 476,150 Unremitted non-U.S. earnings 73,385 91,539 Lease Assets 32,127 25,429 Other 7,387 2,221 Total deferred tax liabilities 489,517 620,972 Net deferred tax liability $ (363,304) $ (476,605) (1) In December of 2021, we executed an intra-company transfer in which certain intellectual property rights held by several of our subsidiaries were contributed to a non-U.S. subsidiary. The transfer accelerated certain taxable income into the year ended December 31, 2021; however, the related current tax expense of $73.2 million, which is payable in 2022, was substantially offset by the reversal of existing deferred tax liabilities.
Uncertain Tax Positions for Liabilities Associated with Unrecognized Tax Benefits	Uncertain Tax Positions : The following table is a reconciliation of the beginning and ending balances for liabilities associated with unrecognized tax benefits for the years ended December 31, 2021, 2020 and 2019: 2021 2020 2019 Balance at January 1 $ 7,230 $ 7,561 $ 8,106 Increase in unrecognized tax benefits related to prior years — 1,286 351 Decrease in unrecognized tax benefits related to prior years — — (201) Unrecognized tax benefits related to the current year — — 1,237 Reductions in unrecognized tax benefits due to lapse of applicable statute of limitations (956) (1,864) (1,881) Increase (decrease) in unrecognized tax benefits due to foreign currency translation (169) 247 (51) Balance at December 31 $ 6,105 $ 7,230 $ 7,561
Examinations by Major Tax Jurisdictions	The taxable years for which the applicable statute of limitations remains open by major tax jurisdictions are as follows: Beginning Ending U.S. 2018 2021 Canada 2017 2021 China 2016 2021 Czech Republic 2018 2021 France 2019 2021 Germany 2011 2021 India 2002 2021 Ireland 2017 2021 Italy 2016 2021 Malaysia 2017 2021 Singapore 2017 2021
Schedule of Cash Flow, Supplemental Disclosures, Income Tax	Supplemental cash flow information Year Ended December 31, 2021 2020 2019 Income taxes paid, net of refunds $ 108,609 $ 77,163 $ 73,632

Pension and other postretirem_2

Pension and other postretirement benefits (Tables)	12 Months Ended
Pension and other postretirement benefits (Tables)	Dec. 31, 2021
Retirement Benefits [Abstract]
Net Benefit Cost of Pension and Postretirement Benefit Plans	The following table provides information regarding the components of the net benefit (income) expense of the pension and postretirement benefit plans for the years ended December 31, 2021, 2020 and 2019: Pension Other Benefits 2021 2020 2019 2021 2020 2019 Service cost $ 1,467 $ 1,416 $ 2,768 $ — $ — $ 9 Interest cost 9,272 12,827 16,000 418 902 1,391 Expected return on plan assets (30,726) (31,650) (27,426) — — — Net amortization and deferral 8,589 7,447 7,013 (1,058) (161) (1) Net benefit (income) expense $ (11,398) $ (9,960) $ (1,645) $ (640) $ 741 $ 1,399
Weighted Average Assumptions used in Determining Net Periodic Benefit Cost	The following table provides the weighted average assumptions for U.S. and foreign plans used in determining net benefit cost: Pension Other Benefits 2021 2020 2019 2021 2020 2019 Discount rate 2.5 % 3.2 % 4.3 % 2.3 % 3.1 % 4.2 % Rate of return 6.7 % 7.5 % 7.7 % Initial healthcare trend rate 6.8 % 7.0 % 7.4 % Ultimate healthcare trend rate 4.5 % 5.0 % 5.0 % The following table provides the weighted average assumptions for U.S. and foreign plans used in determining benefit obligations: Pension Other Benefits 2021 2020 2021 2020 Discount rate 2.8 % 2.5 % 2.7 % 2.3 % Rate of compensation increase 2.8 % 2.8 % Initial healthcare trend rate 6.0 % 6.4 % Ultimate healthcare trend rate 4.5 % 4.5 %
Pension and Postretirement Benefit Plans	The following table provides summarized information with respect to the pension and postretirement benefit plans, measured as of December 31, 2021 and 2020: Pension Other Benefits 2021 2020 2021 2020 Benefit obligation, beginning of year $ 501,347 $ 470,236 $ 31,921 $ 40,042 Service cost 1,467 1,416 — — Interest cost 9,272 12,827 418 902 Actuarial (gain) loss (13,567) 36,726 (2,288) 964 Currency translation (1,726) 2,273 — — Benefits paid (21,138) (21,092) (3,303) (5,448) Medicare Part D reimbursement — — 56 119 Plan amendments — 47 — (4,658) Administrative costs (981) (1,086) — — Projected benefit obligation, end of year 474,674 501,347 26,804 31,921 Fair value of plan assets, beginning of year 457,626 423,300 Actual return on plan assets 22,124 43,276 Contributions 12,159 12,490 Benefits paid (21,138) (21,092) Administrative costs (981) (1,086) Currency translation 3 738 Fair value of plan assets, end of year 469,793 457,626 Funded status, end of year $ (4,881) $ (43,721) $ (26,804) $ (31,921)
Amounts Recognized in the Consolidated Balance Sheet	The following table sets forth the amounts recognized in the consolidated balance sheet with respect to the pension and postretirement plans: Pension Other Benefits 2021 2020 2021 2020 Other assets $ 17,827 $ 3,703 $ — $ — Payroll and benefit-related liabilities (1,602) (1,721) (2,725) (3,125) Pension and postretirement benefit liabilities (21,106) (45,703) (24,079) (28,796) Accumulated other comprehensive loss (gain) 218,139 232,540 (2,847) (1,617) $ 213,258 $ 188,819 $ (29,651) $ (33,538)
Amounts Recognized in Accumulated Other Comprehensive (Income) Loss	The following tables set forth the amounts recognized in accumulated other comprehensive income with respect to the plans: Pension Prior Service Cost Net (Gain) or Loss Deferred Taxes Accumulated Other Comprehensive Balance at December 31, 2019 $ 173 $ 213,816 $ (76,270) $ 137,719 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral (15) (7,432) 1,738 (5,709) Amounts arising during the period: Actuarial changes in benefit obligation — 25,100 (5,875) 19,225 Plan amendments 47 — (9) 38 Impact of currency translation — 851 (241) 610 Balance at December 31, 2020 205 232,335 (80,657) 151,883 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral (5) (8,584) 1,999 (6,590) Amounts arising during the period: Actuarial changes in benefit obligation — (4,965) 1,148 (3,817) Impact of currency translation — (847) 237 (610) Balance at December 31, 2021 $ 200 $ 217,939 $ (77,273) $ 140,866 Other Benefits Prior Service Cost Net (Gain) or Loss Deferred Taxes Accumulated Other Comprehensive Balance at December 31, 2019 $ 7 $ 1,909 $ (825) $ 1,091 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral (18) 179 (37) 124 Amounts arising during the period: Actuarial changes in benefit obligation — 964 (223) 741 Plan amendments (4,658) — 1,076 (3,582) Balance at December 31, 2020 (4,669) 3,052 (9) (1,626) Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral 1,017 41 (243) 815 Amounts arising during the period: Actuarial changes in benefit obligation — (2,288) 523 (1,765) Balance at December 31, 2021 $ (3,652) $ 805 $ 271 $ (2,576)
Fair Values of Pension Plan Assets	The following table provides the fair values of the pension plan assets at December 31, 2021 by asset category: Fair Value Measurements Asset Category (a) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash $ 923 $ 923 — — Money market funds 6 6 — — Equity securities: Managed volatility (b) 57,252 57,252 — — U.S. small/mid-cap equity (c) 7,532 7,532 — — World equity (excluding U.S.) (d) 34,287 34,287 — — Fixed income securities: Intermediate duration fund (e) 101,363 101,363 — — Long duration bond fund (f) 171,919 171,919 — — Corporate bond fund (g) 7,607 7,607 — — Emerging markets debt fund (h) 7,605 7,605 — — Corporate, government and foreign bonds 50,599 50,599 — — Absolute return credit fund (i) 671 — $ 671 — Asset backed – home loans 208 — 208 — Other types of investments: Contract with insurance company (j) 19,130 — — $ 19,130 Other 3 — — 3 Total investments at fair value $ 459,105 $ 439,093 $ 879 $ 19,133 Investments measured at net asset value (k) 10,688 Total $ 469,793 The following table provides the fair values of the pension plan assets at December 31, 2020 by asset category: Fair Value Measurements Asset Category (a) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash $ 582 $ 582 — — Money market funds 12 12 — — Equity securities: Managed volatility (b) 85,974 85,974 — — U.S. small/mid-cap equity (c) 11,780 11,780 — — World equity (excluding U.S.) (d) 59,467 59,467 — — Common equity securities – Teleflex Incorporated 29,592 29,592 — — Fixed income securities: Intermediate duration fund (e) 63,376 63,376 — — Long duration bond fund (f) 98,996 98,996 — — Corporate bond fund (g) 13,469 13,469 — — Emerging markets debt fund (h) 11,412 11,412 — — Corporate, government and foreign bonds 35,582 35,582 — — Asset backed – home loans 261 — $ 261 — Other types of investments: Multi asset funds (l) 8,890 4,057 4,833 — Contract with insurance company (j) 10,485 — — $ 10,485 Other 4 — — 4 Total investments at fair value $ 429,882 $ 414,299 $ 5,094 $ 10,489 Investments measured at Net asset value (k) 27,744 Total $ 457,626 (a) Information on asset categories described in notes (b)-(l) is derived from prospectuses and other material provided by the respective funds comprising the respective asset categories. (b) This category comprises mutual funds that invest in securities of U.S. and non-U.S. companies of all capitalization ranges that exhibit relatively low volatility. (c) This category comprises a mutual fund that invests at least 80% of its net assets in equity securities of small and mid-sized companies. The fund invests in common stocks or exchange traded funds holding common stock of U.S. companies with market capitalizations in the range of companies in the Russell 2500 Index. (d) This category comprises a mutual fund that invests at least 80% of its net assets in equity securities of foreign companies. These securities may include common stocks, preferred stocks, warrants, exchange traded funds based on an international equity index, derivative instruments whose value is based on an international equity index and derivative instruments whose value is based on an underlying equity security or a basket of equity securities. The fund invests in securities of foreign issuers located in developed and emerging market countries. However, the fund will not invest more than 35% of its assets in the common stocks or other equity securities of issuers located in emerging market countries. (e) This category comprises a mutual fund that invests in instruments or derivatives having economic characteristics similar to fixed income securities. The fund invests in investment grade fixed income instruments, including U.S. and foreign corporate obligations, fixed income securities issued by sovereigns or agencies in both developed and emerging foreign markets, debt obligations issued by governments or other municipalities, and securities issued or guaranteed by the U.S. Government and its agencies. The fund will seek to maintain an effective average duration between three (f) This category comprises a mutual fund that invests in instruments or derivatives having economic characteristics similar to fixed income securities. The fund invests in investment grade fixed income instruments, including securities issued or guaranteed by the U.S. Government and its agencies and instrumentalities, corporate bonds, asset-backed securities, exchange traded funds, mortgage-backed securities and collateralized mortgage-backed securities. The fund invests primarily in long duration government and corporate fixed income securities, and uses derivative instruments, including interest rate swap agreements and Treasury futures contracts, for the purpose of managing the overall duration and yield curve exposure of the Fund’s portfolio of fixed income securities. (g) This category comprises funds that invest primarily in higher-yielding fixed income securities, including corporate bonds and debentures, convertible and preferred securities and zero coupon obligations. (h) This category comprises a mutual fund that invests at least 80% of its net assets in fixed income securities of emerging market issuers, primarily in U.S. dollar-denominated debt of foreign governments, government-related and corporate issuers in emerging market countries and entities organized to restructure the debt of those issuers. (i) This category comprises a mutual fund that invests primarily in investment grade bonds and similar fixed income and floating rate securities. (j) This category comprises the asset established out of an agreement to purchase a bulk-annuity policy from an insurer to fully cover the liabilities for members of the pension plan. The asset value is based on the fair value of the contract as determined by the insurance company using inputs that are not observable. (k) This category comprises pooled institutional investments, primarily collective investment trusts. These funds are not listed on an exchange or traded in an active market and these investments are valued using their net asset value, which is generally based on the underlying asset values of the pooled investments held in the trusts. This category comprises the following funds: • a fund that invests primarily in collateralized debt obligations and other structured credit vehicles and may include fixed income securities, loan participations, credit-linked notes, medium-term notes, pooled investment vehicles and derivative instruments. • a hedge fund that invests in various other hedge funds. • funds that invest in underlying funds that acquire, manage, and dispose of real estate properties, with a focus on properties in the U.S. and the UK markets. (l) This category comprises funds that may invest in equities, bonds, or derivatives.
Expected Benefit Payments	The following table provides information about the expected benefit payments under its U.S. and foreign plans for each of the five succeeding years and the aggregate of the five years thereafter, net of the annual average Medicare Part D subsidy of approximately $0.1 million: Pension Other Benefits 2022 $ 22,732 $ 2,723 2023 22,859 2,630 2024 23,583 2,432 2025 23,976 2,348 2026 24,622 2,073 Years 2027 — 2031 127,007 7,388

Business segments and other i_2

Business segments and other information (Tables)	12 Months Ended
Business segments and other information (Tables)	Dec. 31, 2021
Segment Reporting [Abstract]
Business segments and other information	The following tables present our segment results for the years ended December 31, 2021, 2020 and 2019: Year Ended December 31, 2021 2020 2019 Americas $ 1,659,309 $ 1,465,035 $ 1,492,274 EMEA 606,807 584,859 588,043 Asia 297,766 267,016 294,328 OEM 245,681 220,246 220,717 Net revenues $ 2,809,563 $ 2,537,156 $ 2,595,362 Year Ended December 31, 2021 2020 2019 Americas $ 424,225 $ 401,391 $ 319,933 EMEA 94,865 81,348 94,424 Asia 84,648 51,238 73,090 OEM 56,210 44,852 57,994 Total segment operating profit (1) 659,948 578,829 545,441 Unallocated expenses (2) (31,853) (155,761) (118,187) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 628,095 $ 423,068 $ 427,254 (1) Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. For the years ended December 31, 2021, 2020 and 2019, corporate expenses were allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved. Commencing on January 1, 2022, all corporate expenses are allocated amongst the segments in proportion to the respective amounts of net revenues. The revised methodology does not impact period over period comparability because the change was immaterial. (2) Unallocated expenses primarily include manufacturing variances, except for fixed manufacturing cost absorption variances, restructuring and impairment charges and gain on sale of business and assets. Year Ended December 31, 2021 2020 2019 Americas $ 164,102 $ 151,111 $ 153,419 EMEA 45,022 47,012 44,328 Asia 11,140 13,594 14,072 OEM 17,098 15,535 6,550 Consolidated depreciation and amortization $ 237,362 $ 227,252 $ 218,369
Total Net Revenues and Total Net Property, Plant and Equipment by Geographic Region	The following tables provide total net revenues and total net property, plant and equipment by geographic region for the years ended December 31, 2021, 2020 and 2019 and as of December 31, 2021 and 2020, respectively. Year Ended December 31, 2021 2020 2019 Net revenues (based on selling location): U.S. $ 1,769,488 $ 1,567,144 $ 1,606,248 Europe 665,000 646,577 652,069 Asia Pacific 263,022 230,267 241,278 All other 112,053 93,168 95,767 $ 2,809,563 $ 2,537,156 $ 2,595,362 As of December 31, Net property, plant and equipment: 2021 2020 U.S. $ 206,876 $ 234,186 Malaysia 72,541 71,760 Mexico 69,471 69,330 All other 94,870 98,636 $ 443,758 $ 473,912

Summary of significant accoun_3

Summary of significant accounting policies - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Summary Of Significant Accounting Policies [Line Items]
Allowance for credit losses	$ 10.8	$ 12.9
Current portion of allowance for credit losses	$ 6	8.1
Weighted average amortization period of intangible assets, in years	15 years
Reserve for returns and allowances	$ 15.2	14.6
Reserve for estimated rebates	$ 26.4	$ 28.5
Sales Revenue, Net \| Hospitals And Healthcare Providers \| Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	89.00%
Sales Revenue, Net \| Other Medical Device Manufacturers \| Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	9.00%
Sales Revenue, Net \| Home Care Providers such as Pharmacies \| Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	2.00%
Minimum \| Intellectual property
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	5 years
Minimum \| Customer relationships
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	8 years
Minimum \| Distribution rights
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	10 years
Minimum \| Trade names
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	5 years
Minimum \| Non-complete agreement
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	5 years
Maximum \| Intellectual property
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	20 years
Maximum \| Customer relationships
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	27 years
Maximum \| Trade names
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	30 years
Maximum \| Non-complete agreement
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	6 years
Building
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	30 years
Machinery and Equipment \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	3 years
Machinery and Equipment \| Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	15 years
Computer Equipment and Software \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	3 years
Computer Equipment and Software \| Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	10 years

Net revenues - Other revenues (

Net revenues - Other revenues (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Net revenues	$ 2,809,563	$ 2,537,156	$ 2,595,362
Vascular access
Disaggregation of Revenue [Line Items]
Net revenues	700,240	657,703	600,874
Anesthesia
Disaggregation of Revenue [Line Items]
Net revenues	380,140	302,293	338,413
Interventional
Disaggregation of Revenue [Line Items]
Net revenues	427,500	382,435	427,563
Surgical
Disaggregation of Revenue [Line Items]
Net revenues	377,756	317,200	370,074
Interventional urology
Disaggregation of Revenue [Line Items]
Net revenues	341,661	290,022	290,449
OEM
Disaggregation of Revenue [Line Items]
Net revenues	245,681	220,246	220,717
Other
Disaggregation of Revenue [Line Items]
Net revenues	$ 336,585	$ 367,257	$ 347,272

Acquisitions and Divestitures -

Acquisitions and Divestitures - Additional Information (Details) - USD ($) $ in Thousands	Jun. 28, 2021	Dec. 28, 2020	Feb. 18, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2023	May 15, 2021
Business Acquisition [Line Items]
Proceeds from sale of assets				$ 224,909	$ 1,400	$ 14,345
Net gain on sales of business and assets				91,157	0	6,077
Goodwill				2,504,202	2,585,966	$ 2,245,305
IWG High Performance Conductors, Inc.
Business Acquisition [Line Items]
Business combination, consideration transferred			$ 260,000
Goodwill			107,100
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets			179,000
Business combination, recognized identifiable assets acquired and liabilities assumed, deferred tax liabilities			$ 43,400
Acquisition revenue				38,600	27,100
Z-Medica, LLC
Business Acquisition [Line Items]
Business combination, consideration transferred		$ 500,000
Goodwill		186,000
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets		332,000
Business combination, recognized identifiable assets acquired and liabilities assumed, deferred tax liabilities		32,200
Acquisition revenue				66,400
Acquisition operating profit				21,800
Aggregate contingent consideration amount		$ 25,000
Medline Manufacturing And Supply Transition Agreement
Business Acquisition [Line Items]
Contract with customer, related party liability	$ 33,800
Revenue from related parties				51,100
Respiratory Business \| Disposal Group, Held-for-sale, Not Discontinued Operations
Business Acquisition [Line Items]
Disposal group, including discontinued operation, consideration								$ 286,000
Disposal group, including discontinued operation, working capital								$ 12,000
Proceeds from sale of assets	$ 259,000
Goodwill				35,745
Revenue attributable to respiratory business				$ 60,700	$ 138,500
Respiratory Business \| Disposal Group, Held-for-sale, Not Discontinued Operations \| Forecast
Business Acquisition [Line Items]
Proceeds from sale of assets							$ 15,000

Acquisitions and Divestitures_2

Acquisitions and Divestitures - Assets held-for-sale (Details) - Respiratory Business - Disposal Group, Held-for-sale, Not Discontinued Operations $ in Thousands	Dec. 31, 2021USD ($)
Assets
Inventories	$ 26,830
Current assets	26,830
Property, plant and equipment, net	17,006
Intangible assets, net	41,583
Goodwill	35,745
Operating lease assets	1,053
Other assets	94
Noncurrent assets	95,481
Total assets	122,311
Liabilities
Other current liabilities	535
Noncurrent operating lease liabilities	568
Liabilities	$ 1,103

Restructuring and impairment _2

Restructuring and impairment charges - Expected costs to be incurred (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Respiratory divestiture plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 24
Respiratory divestiture plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	30
2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Aggregate restructuring charges	15.6
Restructuring expenses	13
Aggregate restructuring related charges	34.1
2019 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	54
Expected cash outlays	48
Expected capital expenditures	31
2019 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	60
Expected cash outlays	54
Expected capital expenditures	33
2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Aggregate restructuring charges	62.5
Restructuring expenses	10.7
Aggregate restructuring related charges	27.4
2018 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	110
Expected cash outlays	99
Expected capital expenditures	15
2018 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	128
Expected cash outlays	122
Expected capital expenditures	16
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Aggregate restructuring charges	13.8
Restructuring expenses	2.6
Aggregate restructuring related charges	38.6
2014 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	53
Expected cash outlays	43
Expected capital expenditures	26
2014 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	55
Expected cash outlays	46
Expected capital expenditures	27
Termination benefits \| Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	3.3
Termination benefits \| 2019 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	14
Termination benefits \| 2019 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	15
Termination benefits \| 2018 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	60
Termination benefits \| 2018 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	65
Termination benefits \| 2014 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	13
Termination benefits \| 2014 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	13
Other costs \| 2019 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2
Other costs \| 2019 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2
Other costs \| 2018 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	3
Other costs \| 2018 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4
Other costs \| 2014 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	1
Other costs \| 2014 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2
Restructuring charges \| Respiratory divestiture plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	5
Restructuring charges \| Respiratory divestiture plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	8
Restructuring charges \| 2019 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	16
Restructuring charges \| 2019 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	17
Restructuring charges \| 2018 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	63
Restructuring charges \| 2018 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	69
Restructuring charges \| 2014 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	14
Restructuring charges \| 2014 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	15
Restructuring related charges \| Respiratory divestiture plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	19
Restructuring related charges \| Respiratory divestiture plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	22
Restructuring related charges \| 2019 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	38
Restructuring related charges \| 2019 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	43
Restructuring related charges \| 2018 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	47
Restructuring related charges \| 2018 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	59
Restructuring related charges \| 2014 Footprint realignment plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	39
Restructuring related charges \| 2014 Footprint realignment plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 40

Restructuring and impairment _3

Restructuring and impairment charges - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
Asset impairment charges	$ 6,739	$ 21,388	$ 6,966
Respiratory divestiture plan \| Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	3,300
Minimum \| Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Aggregate capital expenditures	22,000
Maximum \| Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Aggregate capital expenditures	$ 28,000

Restructuring and impairment _4

Restructuring and impairment charges - Reconciliation of changes in accrued liabilities associated with restructuring program (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Respiratory divestiture plan
Restructuring Reserve [Roll Forward]
Balance, beginning	$ 0	$ 0
Subsequent accruals	2,694	0
Cash payments	(7)	0
Foreign currency translation and other	(86)	0
Balance, ending	2,601	0
2019 Footprint realignment plan
Restructuring Reserve [Roll Forward]
Balance, beginning	8,054	11,870
Subsequent accruals	253	1,542
Cash payments	(4,982)	(5,532)
Foreign currency translation and other	(19)	174
Balance, ending	3,306	8,054
2018 Footprint realignment plan
Restructuring Reserve [Roll Forward]
Balance, beginning	50,081	44,274
Subsequent accruals	2,476	5,948
Cash payments	(4,813)	(4,281)
Foreign currency translation and other	(3,679)	4,140
Balance, ending	44,065	50,081
2014 Footprint realignment plan
Restructuring Reserve [Roll Forward]
Balance, beginning	3,593	3,669
Subsequent accruals	262	606
Cash payments	(947)	(682)
Foreign currency translation and other	0	0
Balance, ending	$ 2,908	$ 3,593

Restructuring and impairment _5

Restructuring and impairment charges - Restructuring program (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	$ 14,999	$ 17,103	$ 15,239
Asset impairment charges	6,739	21,388	6,966
Total restructuring and impairment charges	21,738	38,491	22,205
Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	2,694
2021 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	7,357
2020 Workforce reduction plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		8,847
2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	253	1,542	13,753
2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	2,476	5,948	(939)
Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	2,219	766	2,425
Termination benefits
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	11,762	14,634	12,683
Asset impairment charges	0	0	0
Total restructuring and impairment charges	11,762	14,634	12,683
Termination benefits \| Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	2,687
Termination benefits \| 2021 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	7,280
Termination benefits \| 2020 Workforce reduction plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		8,494
Termination benefits \| 2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	(111)	647	13,683
Termination benefits \| 2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	2,335	5,565	(1,787)
Termination benefits \| Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	(429)	(72)	787
Other costs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	3,237	2,469	2,556
Asset impairment charges	6,739	21,388	6,966
Total restructuring and impairment charges	9,976	23,857	9,522
Other costs \| Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	7
Other costs \| 2021 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	77
Other costs \| 2020 Workforce reduction plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		353
Other costs \| 2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	364	895	70
Other costs \| 2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	141	383	848
Other costs \| Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	$ 2,648	$ 838	$ 1,638

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 146,433	$ 132,370
Work-in-process	81,503	75,874
Finished goods	249,707	304,952
Inventory, Net	$ 477,643	$ 513,196

Property, plant, equipment (Det

Property, plant, equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Land, buildings and leasehold improvements	$ 285,305	$ 272,637
Machinery and equipment	475,040	496,664
Computer equipment and software	191,605	172,913
Construction in progress	49,782	84,336
Property, plant and equipment, gross	1,001,732	1,026,550
Less: Accumulated depreciation	(557,974)	(552,638)
Property, plant and equipment, net	$ 443,758	$ 473,912

Goodwill and other intangible_3

Goodwill and other intangible assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Intangible asset amortization expense	$ 165,604	$ 158,685	$ 149,974
Trade names
Finite-Lived Intangible Assets [Line Items]
Indefinite lived intangible assets	$ 234,700

Goodwill and other intangible_4

Goodwill and other intangible assets - Changes in carrying amount by reporting segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill [Line Items]
Goodwill			$ 2,577,433
Accumulated impairment losses			(332,128)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 2,585,966	$ 2,245,305
Goodwill related to acquisitions		295,066
Translation and other adjustments	(44,064)	45,595
Goodwill disposed	(35,745)
Goodwill related to acquisitions	(1,955)
Goodwill, ending balance	2,504,202	2,585,966
Americas \| Operating Segments
Goodwill [Line Items]
Goodwill			1,883,053
Accumulated impairment losses			(332,128)
Goodwill [Roll Forward]
Goodwill, beginning balance	1,700,282	1,550,925
Goodwill related to acquisitions		149,877
Translation and other adjustments	(696)	(520)
Goodwill disposed	(21,802)
Goodwill related to acquisitions	(1,560)
Goodwill, ending balance	1,676,224	1,700,282
EMEA \| Operating Segments
Goodwill [Line Items]
Goodwill			475,772
Accumulated impairment losses			0
Goodwill [Roll Forward]
Goodwill, beginning balance	536,228	475,772
Goodwill related to acquisitions		22,364
Translation and other adjustments	(36,310)	38,092
Goodwill disposed	(7,537)
Goodwill related to acquisitions	(232)
Goodwill, ending balance	492,149	536,228
Asia \| Operating Segments
Goodwill [Line Items]
Goodwill			213,725
Accumulated impairment losses			0
Goodwill [Roll Forward]
Goodwill, beginning balance	237,446	213,725
Goodwill related to acquisitions		15,698
Translation and other adjustments	(7,058)	8,023
Goodwill disposed	(6,406)
Goodwill related to acquisitions	(163)
Goodwill, ending balance	223,819	237,446
OEM \| Operating Segments
Goodwill [Line Items]
Goodwill			4,883
Accumulated impairment losses			$ 0
Goodwill [Roll Forward]
Goodwill, beginning balance	112,010	4,883
Goodwill related to acquisitions		107,127
Translation and other adjustments	0	0
Goodwill disposed	0
Goodwill related to acquisitions	0
Goodwill, ending balance	$ 112,010	$ 112,010

Goodwill and other intangible_5

Goodwill and other intangible assets - Components of intangible assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	$ 3,392,898	$ 3,534,799
Accumulated Amortization	(1,103,831)	(1,015,053)
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Indefinite lived intangible assets	28,158	29,627
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,328,611	1,377,943
Accumulated Amortization	(441,059)	(425,692)
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,440,643	1,458,924
Accumulated Amortization	(560,740)	(479,612)
Distribution rights
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	23,434	23,866
Accumulated Amortization	(20,630)	(20,280)
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	549,269	619,847
Accumulated Amortization	(59,249)	(65,955)
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	22,783	24,592
Accumulated Amortization	$ (22,153)	$ (23,514)

Goodwill and other intangible_6

Goodwill and other intangible assets - Estimated annual amortization expense (Detail) $ in Thousands	Dec. 31, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 160,600
2023	154,800
2024	153,000
2025	151,800
2026	$ 148,800

Leases - Additional information

Leases - Additional information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Lease, cost	$ 32.6	$ 30.7	$ 30.2
Minimum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, option to terminate or extend	1 year

Leases - Maturities of lease li

Leases - Maturities of lease liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2022	$ 26,682
2023	22,790
2024	19,279
2025	14,789
2026	15,307
2027 and thereafter	61,950
Total lease payments	160,797
Less: interest	(22,634)
Present value of lease liabilities	$ 138,163	$ 108,743

Leases - Supplemental balance s

Leases - Supplemental balance sheet information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Lease liabilities	$ 138,163	$ 108,743
Cash paid for amounts included in the measurement of lease liabilities within operating cash flows	29,199	28,276
Right of use assets obtained in exchange for operating lease obligations	$ 55,290	$ 8,904
Weighted average remaining lease term	7 years 10 months 24 days	6 years 8 months 12 days
Weighted average discount rate	3.70%	4.00%

Borrowings - Components of Long

Borrowings - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Apr. 29, 2021	May 27, 2020	Nov. 20, 2017
Line of Credit Facility [Line Items]
Long-term debt, Gross	$ 1,863,500	$ 2,498,000
Less: Unamortized debt issuance costs	(13,398)	(19,612)
Net carrying amount	1,850,102	2,478,388
Current portion of borrowings	(110,000)	(100,500)
Long-term borrowings	1,740,102	2,377,888
Revolving Credit Facility
Line of Credit Facility [Line Items]
Long-term line of credit	$ 141,000	$ 350,000
Senior credit facility interest rate	1.48%	1.66%
Securitization Program
Line of Credit Facility [Line Items]
Long-term line of credit		$ 75,000
Securitization program, at a rate of 1.00% at December 31, 2021 and 1.24% at December 31, 2020	$ 75,000	$ 75,000
Interest rate	1.00%	1.24%
Term loan facility, at a rate of 1.48% at December 31, 2021 and 1.65% at December 31 2020, due 2024 \| Term Loan
Line of Credit Facility [Line Items]
Long-term line of credit	$ 647,500	$ 673,000
Senior credit facility interest rate	1.48%	1.65%
4.875% Senior Notes due 2026 \| Senior Notes
Line of Credit Facility [Line Items]
Senior notes	$ 0	$ 400,000	$ 400,000
Interest rate	4.875%	4.875%	4.875%
4.625% Senior Notes due 2027 \| Senior Notes
Line of Credit Facility [Line Items]
Senior notes	$ 500,000	$ 500,000			$ 500,000
Interest rate	4.625%	4.625%			4.625%
4.25% Senior Notes due 2028 \| Senior Notes
Line of Credit Facility [Line Items]
Senior notes	$ 500,000	$ 500,000		$ 500,000
Interest rate	4.25%	4.25%		4.25%

Borrowings - Additional Informa

Borrowings - Additional Information (Detail) - USD ($)	Apr. 29, 2021	May 27, 2020	Nov. 20, 2017	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Mar. 30, 2020	Mar. 29, 2020
Debt Instrument [Line Items]
Loss on extinguishment of debt				$ 12,986,000	$ 0	$ 8,822,000
Securitization Program
Debt Instrument [Line Items]
Interest rate				1.00%	1.24%
Maximum amount available under receivable securitization							$ 75,000,000	$ 50,000,000
Long-term line of credit					$ 75,000,000
Securitization program, at a rate of 1.00% at December 31, 2021 and 1.24% at December 31, 2020				$ 75,000,000	75,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Long-term line of credit				$ 141,000,000	$ 350,000,000
4.875% Senior Notes due 2026 \| Senior Notes
Debt Instrument [Line Items]
Interest rate	4.875%			4.875%	4.875%
Senior notes	$ 400,000,000			$ 0	$ 400,000,000
Percent of redemption price to principal amount on redemption	102.438%
Loss on extinguishment of debt	$ 13,000,000
Credit Agreement
Debt Instrument [Line Items]
Interest rate						2.00%
Credit Agreement \| LIBOR \| Minimum
Debt Instrument [Line Items]
Basis spread on variable rate						1.25%
Credit Agreement \| LIBOR \| Maximum
Debt Instrument [Line Items]
Basis spread on variable rate						2.00%
Credit Agreement \| Federal Funds
Debt Instrument [Line Items]
Basis spread on variable rate						0.50%
Credit Agreement \| Adjusted LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate						1.00%
Credit Agreement \| Adjusted LIBOR \| Minimum
Debt Instrument [Line Items]
Basis spread on variable rate						0.125%
Credit Agreement \| Adjusted LIBOR \| Maximum
Debt Instrument [Line Items]
Basis spread on variable rate						1.00%
Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term						5 years
Maximum amount available for borrowing						$ 1,000,000,000
Credit Agreement \| Term Loan
Debt Instrument [Line Items]
Maximum amount available for borrowing						$ 700,000,000
4.625% Senior Notes due 2027 \| Minimum
Debt Instrument [Line Items]
Declining percent of redemption price to principal amount			0.771%
4.625% Senior Notes due 2027 \| Maximum
Debt Instrument [Line Items]
Declining percent of redemption price to principal amount			100.00%
4.625% Senior Notes due 2027 \| Senior Notes
Debt Instrument [Line Items]
Interest rate			4.625%	4.625%	4.625%
Senior notes			$ 500,000,000	$ 500,000,000	$ 500,000,000
Basis spread on variable rate			0.50%
Debt issuance, line of credit			$ 7,900,000
4.625% Senior Notes due 2027 \| Senior Notes \| Maximum
Debt Instrument [Line Items]
Percent of redemption price to principal amount			102.313%
4.625% Senior Notes due 2027 \| Senior Notes \| Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Percent of redemption price to principal amount on redemption			100.00%
Makewhole premium as percentage of principal amount of notes subject to redemption			1.00%
4.625% Senior Notes due 2027 \| Senior Notes \| Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Percent of redemption price to principal amount on redemption			104.625%
Percent of principal amount of notes redeemable			40.00%
4.25% Senior Notes due 2028 \| Minimum
Debt Instrument [Line Items]
Declining percent of redemption price to principal amount		1.0625%
4.25% Senior Notes due 2028 \| Maximum
Debt Instrument [Line Items]
Declining percent of redemption price to principal amount		100.00%
4.25% Senior Notes due 2028 \| Senior Notes
Debt Instrument [Line Items]
Interest rate		4.25%		4.25%	4.25%
Senior notes		$ 500,000,000		$ 500,000,000	$ 500,000,000
Percent of redemption price to principal amount on redemption		100.00%
Basis spread on variable rate		0.50%
Debt issuance, line of credit		$ 8,500,000
Percent of redemption price to principal amount		102.125%
4.25% Senior Notes due 2028 \| Senior Notes \| Debt Instrument, Redemption, Period Three
Debt Instrument [Line Items]
Percent of redemption price to principal amount on redemption		104.25%
Makewhole premium as percentage of principal amount of notes subject to redemption		1.00%
Percent of principal amount of notes redeemable		40.00%
Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Leverage ratio, required						4.50
Interest coverage ratio, required						3.50

Borrowings - Fair Value of Debt

Borrowings - Fair Value of Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Level 2
Fair Value Measurements [Line Items]
Fair value of debt	$ 1,893,518	$ 2,586,058

Borrowings - Aggregate Amounts

Borrowings - Aggregate Amounts of Long-Term Debt (Detail) $ in Thousands	Dec. 31, 2021USD ($)
Debt Disclosure [Abstract]
2022	$ 110,000
2023	43,750
2024	709,750
2025	0
2026 and thereafter	$ 1,000,000

Borrowings - Supplemental Cash

Borrowings - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Cash interest paid	$ 73,598	$ 79,533	$ 95,954

Financial instruments - Additio

Financial instruments - Additional Information (Detail)	12 Months Ended
Financial instruments - Additional Information (Detail)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)Financial_Institution_Counterparty	Dec. 31, 2019USD ($)Financial_Institution_Counterparty	Dec. 31, 2020EUR (€)Financial_Institution_Counterparty	Dec. 31, 2019EUR (€)Financial_Institution_Counterparty
Cash Flow Hedging
Derivatives Fair Value [Line Items]
Ineffectiveness on hedging derivatives	$ 0	$ 0	$ 0
Not Designated as Hedging Instrument \| Foreign Currency Exchange Contracts
Derivatives Fair Value [Line Items]
Loss on derivative	8,900,000	1,800,000
Total notional amount for all open foreign currency forward contracts	161,200,000	163,500,000
Designated as Hedging Instrument \| Foreign Currency Exchange Contracts \| Cash Flow Hedging
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	$ 149,500,000	129,500,000
Designated as Hedging Instrument \| Cross Currency Interest Rate Contract
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts		$ 250,000,000	$ 500,000,000	€ 219,200,000	€ 433,900,000
Derivative, number of instruments held \| Financial_Institution_Counterparty		5	6	5	6
Derivative, fixed interest rate		4.875%	4.625%	4.875%	4.625%
Derivative, annual interest rate		2.4595%	1.942%	2.4595%	1.942%

Financial instruments - Fair va

Financial instruments - Fair value of derivatives (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Foreign Currency Exchange Contracts \| Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$ 0	$ 34,125
Cash Flow Hedging
Derivatives Fair Value [Line Items]
Total asset derivatives	33,291	21,858
Total liability derivatives	1,140	35,995
Cash Flow Hedging \| Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	23,731	21,858
Cash Flow Hedging \| Other assets
Derivatives Fair Value [Line Items]
Total asset derivatives	9,560	0
Cash Flow Hedging \| Foreign Currency Exchange Contracts \| Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	1,140	1,870
Cash Flow Hedging \| Foreign Currency Exchange Contracts \| Designated as Hedging Instrument \| Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	1,957	1,691
Cash Flow Hedging \| Foreign Currency Exchange Contracts \| Designated as Hedging Instrument \| Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	993	1,504
Cash Flow Hedging \| Foreign Currency Exchange Contracts \| Not Designated as Hedging Instrument \| Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	56	61
Cash Flow Hedging \| Foreign Currency Exchange Contracts \| Not Designated as Hedging Instrument \| Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	147	366
Cash Flow Hedging \| Cross Currency Interest Rate Contract \| Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	21,718	20,106
Cash Flow Hedging \| Cross Currency Interest Rate Contract \| Other assets
Derivatives Fair Value [Line Items]
Total asset derivatives	9,560	0
Cash Flow Hedging \| Cross Currency Interest Rate Contract \| Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$ 0	$ 34,125

Financial instruments - Schedul

Financial instruments - Schedule of foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency translation adjustments, net of tax of $(5,563), $6,442 and $(6,270), respectively	$ (63,191)	$ 59,758	$ 4,195
Interest benefit on swaps not designed as hedging instrument	19,296	19,178	$ 18,866
Cross Currency Interest Rate Contract \| Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Interest benefit on swaps not designed as hedging instrument	19,296	14,488
Cross Currency Interest Rate Contract \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency translation adjustments, net of tax of $(5,563), $6,442 and $(6,270), respectively	$ 34,849	$ 37,312

Fair value measurement - Financ

Fair value measurement - Financial assets and liabilities carried at fair value measured on recurring basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$ 19,186	$ 12,617
Derivative assets	33,291	21,858
Derivative liabilities	1,140	35,995
Contingent consideration liabilities	9,814	36,633
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	19,186	12,617
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	0	0
Significant Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	33,291	21,858
Derivative liabilities	1,140	35,995
Contingent consideration liabilities	0	0
Significant Unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	$ 9,814	$ 36,633

Fair value measurement - Valuat

Fair value measurement - Valuation Technique (Details) - Discounted cash flow - Discount rate	Dec. 31, 2021
Milestone-based payment \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.019
Milestone-based payment \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.022
Milestone-based payment \| Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.020
Revenue-based \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.017
Revenue-based \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.100
Revenue-based \| Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.061

Fair value measurement - Reconc

Fair value measurement - Reconciliation of changes in three financial liabilities measured at fair value on recurring (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Changes in Level 3 Financial Liabilities Related to Contingent Consideration [Roll Forward]
Beginning balance	$ 36,633	$ 219,908
Payments	(31,678)	(146,971)
Revaluations and other adjustments	4,895	(36,714)
Translation adjustment	(36)	410
Ending balance	9,814	$ 36,633
NeoTract, Inc
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payment for contingent consideration liability	$ 17,400

Shareholders' equity - Addition

Shareholders' equity - Additional Information (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Shareholders Equity [Line Items]
Common shares, authorized (in shares)	200,000,000
Common shares, par value (in dollars per share)	$ 1	$ 1
Preference shares, authorized (in shares)	500,000
Stock Option
Shareholders Equity [Line Items]
Weighted average antidilutive which were not included in the calculation of earnings per share (in shares)	100,000	100,000	100,000

Shareholders' equity - Reconcil

Shareholders' equity - Reconciliation of basic to diluted weighted average common shares outstanding (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Basic (in shares)	46,774	46,488	46,200
Dilutive effect of share based awards (in shares)	653	799	890
Diluted (in shares)	47,427	47,287	47,090

Shareholders' equity - Change i

Shareholders' equity - Change in accumulated other comprehensive income (loss), net of tax (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$ 3,336,457	$ 2,979,320
Other comprehensive (loss) income before reclassifications	(56,648)	39,395
Amounts reclassified from accumulated other comprehensive income	6,987	7,699
Net current-year other comprehensive (loss) income	(49,661)	47,094
Ending Balance	3,754,748	3,336,457
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(482)	735
Other comprehensive (loss) income before reclassifications	351	(3,331)
Amounts reclassified from accumulated other comprehensive income	1,212	2,114
Net current-year other comprehensive (loss) income	1,563	(1,217)
Ending Balance	1,081	(482)
Pension and Other Postretirement Benefit Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(150,257)	(138,810)
Other comprehensive (loss) income before reclassifications	6,192	(17,032)
Amounts reclassified from accumulated other comprehensive income	5,775	5,585
Net current-year other comprehensive (loss) income	11,967	(11,447)
Ending Balance	(138,290)	(150,257)
Foreign Currency Translation Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(146,559)	(206,317)
Other comprehensive (loss) income before reclassifications	(63,191)	59,758
Amounts reclassified from accumulated other comprehensive income	0	0
Net current-year other comprehensive (loss) income	(63,191)	59,758
Ending Balance	(209,750)	(146,559)
Accumulated Other Comprehensive Income (loss)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(297,298)	(344,392)
Ending Balance	$ (346,959)	$ (297,298)

Shareholders' equity - Accumula

Shareholders' equity - Accumulated other comprehensive income (loss) into income expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	$ 1,259,961	$ 1,212,282	$ 1,186,357
Income from continuing operations before taxes	559,468	357,732	339,903
Taxes (benefit) on income from continuing operations	(74,349)	(21,931)	122,078
Net of tax	485,119	335,801	461,981
Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Impact on income from continuing operations, net of tax	6,987	7,699	4,247
Reclassification out of Accumulated Other Comprehensive Income \| Cash Flow Hedges \| Foreign Exchange Forward
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	1,150	2,354	(1,284)
Income from continuing operations before taxes	1,150	2,354	(1,284)
Taxes (benefit) on income from continuing operations	62	(240)	150
Net of tax	1,212	2,114	(1,134)
Reclassification out of Accumulated Other Comprehensive Income \| Pension and Other Postretirement Benefit Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income from continuing operations before taxes	7,531	7,286	7,012
Taxes (benefit) on income from continuing operations	(1,756)	(1,701)	(1,631)
Net of tax	5,775	5,585	5,381
Actuarial losses	8,543	7,253	6,930
Prior-service credits	$ (1,012)	$ 33	$ 82

Stock compensation plans - Addi

Stock compensation plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of common stock authorized to be issued under plan (in shares)	5,300,000
Number of options granted (in shares)	108,686
Unrecognized compensation expense	$ 37.8
Shares available for future grants (in shares)	3,082,554
Stock option granted, weighted average grant date fair value (in dollars per share)	$ 103.87	$ 74.60	$ 68.22
Stock option granted, weighted average grant date fair value	$ 27.4	$ 77.9	$ 64.3
Stock option expenses including selling general and administrative expenses	$ 8.8
Non-vested restricted stock units issued (in shares)	59,210	52,464	69,799
Non vested restricted stock expense including selling general and administrative expense	$ 13.5
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options granted (in shares)	108,686
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant of restricted stock awards (in shares)	59,210
Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense	$ 9.4
Period for recognition	1 year 5 months 19 days
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense	$ 17.7
Period for recognition	1 year 2 months 12 days
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant of restricted stock awards (in shares)	59,210
Weighted average grant date fair value (in dollars per share)	$ 398.59	$ 344.70	$ 286.51
Performance Shares Units (PSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance period	3 years
Weighted average grant date fair value (in dollars per share)		$ 419.25
Minimum \| Performance Shares Units (PSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant of restricted stock awards (in shares)	16,903
Maximum \| Performance Shares Units (PSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant of restricted stock awards (in shares)	42,272

Stock compensation plans - Shar

Stock compensation plans - Share-based Compensation Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock-based compensation	$ 22,937	$ 20,739	$ 26,940
Tax benefit from compensation expense	10,912	21,958	21,121
Net excess tax benefit from compensation expense	$ 6,355	$ 17,549	$ 15,380

Stock compensation plans - Weig

Stock compensation plans - Weighted-average assumptions used to estimate fair value of options granted (Detail) - Stock Options	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Weighted Average Fair Values [Line Items]
Risk-free interest rate	0.67%	1.16%	2.44%
Expected life of option	5 years 3 days	5 years	4 years 11 months 26 days
Expected dividend yield	0.34%	0.39%	0.47%
Expected volatility	30.03%	23.98%	23.92%

Stock compensation plans- Summa

Stock compensation plans- Summary of stock option activity (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Options, Outstanding, beginning of year (in shares) \| shares	1,157,315
Number of Options, Granted (in shares) \| shares	108,686
Number of Options, Exercised (in shares) \| shares	(125,143)
Number of Options, Forfeited or Expired (in shares) \| shares	(32,859)
Number of Options, Outstanding, ending of year (in shares) \| shares	1,107,999
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price, Outstanding, beginning of year (in dollars per share) \| $ / shares	$ 195.57
Weighted Average Exercise Price, Granted (in dollars per share) \| $ / shares	403.99
Weighted Average Exercise Price, Exercised (in dollars per share) \| $ / shares	175.90
Weighted Average Exercise Price, Forfeited or Expired (in dollars per share) \| $ / shares	334.14
Weighted Average Exercise Price, Outstanding, beginning of year (in dollars per share) \| $ / shares	$ 214.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Number of Options, Exercisable, end of year (in shares) \| shares	908,854
Weighted Average Exercise Price, Exercisable, end of year (in dollars per share) \| $ / shares	$ 181.31
Weighted Average Remaining Contractual Life in Years, Outstanding, end of year	5 years 1 month 9 days
Weighted Average Remaining Contractual Life in Years, Exercisable, end of year	4 years 4 months 13 days
Aggregate Intrinsic Value, Outstanding, end of year \| $	$ 136,520
Aggregate Intrinsic Value, Exercisable, end of year \| $	$ 135,036

Stock compensation plans - We_2

Stock compensation plans - Weighted-average assumptions used to estimate fair value of non-vested shares granted (Detail) - Restricted Stock Units	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Weighted Average Fair Values [Line Items]
Risk-free interest rate	0.28%	1.07%	2.41%
Expected dividend yield	0.34%	0.38%	0.46%

Stock compensation plans - Summ

Stock compensation plans - Summary of non vested restricted stock unit activity (Detail) - Restricted Stock Units - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Non-Vested Shares, Outstanding, beginning of the year (in shares)	150,812
Number of Non-Vested Shares, Granted (in shares)	59,210
Number of Non-Vested Shares, Vested (in shares)	(50,098)
Number of Non-Vested Shares, Forfeited (in shares)	(24,546)
Number of Non-Vested Shares, Outstanding, end of the year (in shares)	135,378	150,812
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value, Outstanding, beginning of the year (in dollars per share)	$ 293.10
Weighted Average Grant Date Fair Value, Granted (in dollars per share)	398.59	$ 344.70	$ 286.51
Weighted Average Grant Date Fair Value, Vested (in dollars per share)	260.32
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)	334.38
Weighted Average Grant Date Fair Value, Outstanding, end of the year (in dollars per share)	$ 343.89	$ 293.10
Weighted Average Remaining Contractual Life In Years, Outstanding, end of the year	1 year 2 months 12 days
Aggregate Intrinsic Value, Outstanding, end of the year	$ 44,469

Income taxes - Additional Infor

Income taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Contingency [Line Items]
Cumulative unremitted earnings, non-permanently reinvested	$ 1,300,000
Cumulative unremitted earnings, permanently reinvested	$ 1,000,000
Effective income tax rate, total	13.30%	6.10%	(35.90%)
Realized net benefit as result of reducing our reserves with respect to uncertain tax positions	$ 800	$ 1,700	$ 100
Tax effect, carry forwards	168,100
Deferred tax assets, valuation allowance	143,177	155,008
Unrecognized tax benefits that would impact effective tax rate	3,800
Unrecognized tax benefits, interest (benefit) expense	200	200	200
Unrecognized tax benefits, penalties	(300)	(500)	$ (100)
Unrecognized tax benefits, interest (benefit) expense accrued	800	700
Unrecognized tax benefits, penalties accrued	1,800	$ 2,100
Minimum
Income Tax Contingency [Line Items]
Unrecognized tax benefits change within next twelve months due to potential for resolution of foreign and U.S. examinations	0
Maximum
Income Tax Contingency [Line Items]
Unrecognized tax benefits change within next twelve months due to potential for resolution of foreign and U.S. examinations	1,100
No Expiration Date
Income Tax Contingency [Line Items]
Tax effect, carry forwards	15,700
After 2020 but before the end of 2025
Income Tax Contingency [Line Items]
Tax effect, carry forwards	19,200
After 2025
Income Tax Contingency [Line Items]
Tax effect, carry forwards	$ 133,200

Income taxes - Components of pr

Income taxes - Components of provision for income taxes from continuing operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current:
Federal	$ 134,336	$ 11,148	$ 19,374
State	16,970	9,644	8,220
Non-U.S.	35,399	35,042	23,690
Deferred:
Federal	(85,272)	(9,475)	(2,041)
State	(16,933)	(13,734)	(28,277)
Non-U.S.	(10,151)	(10,694)	(143,044)
Provision for income taxes from continuing operations	$ 74,349	$ 21,931	$ (122,078)

Income taxes - Summary of U.S.

Income taxes - Summary of U.S. and non-U.S. components of income from continuing operations before taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
U.S.	$ 209,231	$ 233,034	$ 89,021
Non-U.S.	350,237	124,698	250,882
Income from continuing operations before taxes	$ 559,468	$ 357,732	$ 339,903

Income taxes - Reconciliations

Income taxes - Reconciliations between statutory federal income tax rate and effective income tax rate (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal statutory rate	21.00%	21.00%	21.00%
Tax effect of international items	(6.00%)	(5.30%)	(11.30%)
Legal entity merger - deferred taxes	0.00%	0.00%	(38.00%)
Excess tax benefits related to share-based compensation	(1.10%)	(4.90%)	(4.50%)
State taxes, net of federal benefit	0.10%	(0.30%)	(4.90%)
Uncertain tax contingencies	(0.10%)	(0.50%)	0.00%
Contingent consideration	0.20%	(2.20%)	3.40%
Intellectual property impairment charge	0.00%	(1.20%)	0.00%
Research and development tax credit	(0.80%)	(1.10%)	(1.10%)
Other, net	0.00%	0.60%	(0.50%)
Effective income tax rate, total	13.30%	6.10%	(35.90%)
Increase (decrease) in deferred tax liability due to merger of foreign subsidiaries			$ (129)

Income taxes - Deferred tax ass

Income taxes - Deferred tax assets and liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Tax loss and credit carryforwards	$ 168,113	$ 180,782
Lease Liabilities	32,127	25,429
Pension	350	12,237
Reserves and accruals	64,421	72,931
Other	4,379	7,996
Less: valuation allowances	(143,177)	(155,008)
Total deferred tax assets	126,213	144,367
Deferred tax liabilities:
Property, plant and equipment	24,479	25,633
Intangibles — stock acquisitions	352,139	476,150
Unremitted non-U.S. earnings	73,385	91,539
Lease Assets	32,127	25,429
Other	7,387	2,221
Total deferred tax liabilities	489,517	620,972
Net deferred tax liability	(363,304)	$ (476,605)
Current income tax expense	$ 73,200

Income taxes - Uncertain tax po

Income taxes - Uncertain tax positions for liabilities associated with unrecognized tax benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 7,230	$ 7,561	$ 8,106
Increase in unrecognized tax benefits related to prior years	0	1,286	351
Decrease in unrecognized tax benefits related to prior years	0	0	(201)
Unrecognized tax benefits related to the current year	0	0	1,237
Reductions in unrecognized tax benefits due to lapse of applicable statute of limitations	(956)	(1,864)	(1,881)
Increase (decrease) in unrecognized tax benefits due to foreign currency translation	(169)		(51)
Increase (decrease) in unrecognized tax benefits due to foreign currency translation		247
Ending balance	$ 6,105	$ 7,230	$ 7,561

Income Taxes - Supplemental Cas

Income Taxes - Supplemental Cash Flow (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income taxes paid, net of refunds	$ 108,609	$ 77,163	$ 73,632

Pension and other postretirem_3

Pension and other postretirement benefits - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Accumulated benefit obligations for plans with accumulated benefit obligations and projected benefit obligations in excess of plan assets	$ 456	$ 481
Projected benefit obligations for plans with accumulated benefit obligations and projected benefit obligations in excess of plan assets	456.6	481.8
Fair value of plan assets for plans with accumulated benefit obligations and projected benefit obligations in excess of plan assets	449.8	434.3
Defined benefit plans, annual average Medicare part D subsidy	0.1
Defined contribution plans, costs	$ 23.2	$ 21.7	$ 17.5
Defined Benefit Plan, Equity Securities
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Target allocation percentage of securities	26.00%
Fixed Income Securities
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Target allocation percentage of securities	74.00%
Pension
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	2.80%	2.50%
Rate of return	6.70%	7.50%	7.70%
Accumulated benefit obligation	$ 474.1	$ 500.6
Expected employer contribution next fiscal year	$ 1.6
Postretirement Health Care Plans
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	2.70%	2.30%
Expected employer contribution next fiscal year	$ 2.7
U.S. \| Pension
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	2.95%
Rate of return	5.80%	7.00%
U.S. \| Postretirement Health Care Plans
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	2.69%
Foreign Plan \| Pension
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets with accumulated benefit obligation in excess of plan assets	$ 2	$ 3.7

Pension and other postretirem_4

Pension and other postretirement benefits - Net benefit cost of pension and postretirement benefit plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Pension
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 1,467	$ 1,416	$ 2,768
Interest cost	9,272	12,827	16,000
Expected return on plan assets	(30,726)	(31,650)	(27,426)
Net amortization and deferral	8,589	7,447	7,013
Net benefit (income) expense	(11,398)	(9,960)	(1,645)
Other Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0	9
Interest cost	418	902	1,391
Expected return on plan assets	0	0	0
Net amortization and deferral	(1,058)	(161)	(1)
Net benefit (income) expense	$ (640)	$ 741	$ 1,399

Pension and other postretirem_5

Pension and other postretirement benefits - Weighted average assumptions used in determining net periodic benefit cost (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Pension
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.50%	3.20%	4.30%
Rate of return	6.70%	7.50%	7.70%
Other Benefits
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.30%	3.10%	4.20%
Initial healthcare trend rate	6.80%	7.00%	7.40%
Ultimate healthcare trend rate	4.50%	5.00%	5.00%

Pension and other postretirem_6

Pension and other postretirement benefits - Summarized information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Pension
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation, beginning of year	$ 501,347	$ 470,236
Service cost	1,467	1,416	$ 2,768
Interest cost	9,272	12,827	16,000
Actuarial (gain) loss	(13,567)	36,726
Currency translation	(1,726)	2,273
Benefits paid	(21,138)	(21,092)
Medicare Part D reimbursement	0	0
Plan amendments	0	47
Administrative costs	(981)	(1,086)
Projected benefit obligation, end of year	474,674	501,347	470,236
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets, beginning of year	457,626	423,300
Actual return on plan assets	22,124	43,276
Contributions	12,159	12,490
Benefits paid	(21,138)	(21,092)
Administrative costs	(981)	(1,086)
Currency translation	3	738
Fair value of plan assets, end of year	469,793	457,626	423,300
Funded status, end of year	(4,881)	(43,721)
Other Benefits
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation, beginning of year	31,921	40,042
Service cost	0	0	9
Interest cost	418	902	1,391
Actuarial (gain) loss	(2,288)	964
Currency translation	0	0
Benefits paid	(3,303)	(5,448)
Medicare Part D reimbursement	56	119
Plan amendments	0	(4,658)
Administrative costs	0	0
Projected benefit obligation, end of year	26,804	31,921	$ 40,042
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Administrative costs	0	0
Funded status, end of year	$ (26,804)	$ (31,921)

Pension and other postretirem_7

Pension and other postretirement benefits - Amounts recognized in consolidated balance sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Payroll and benefit-related liabilities	$ (143,657)	$ (122,366)
Pension and postretirement benefit liabilities	(45,185)	(74,499)
Pension
Defined Benefit Plan Disclosure [Line Items]
Other assets	17,827	3,703
Payroll and benefit-related liabilities	(1,602)	(1,721)
Pension and postretirement benefit liabilities	(21,106)	(45,703)
Accumulated other comprehensive loss (gain)	218,139	232,540
Amounts recognized in balance sheet	213,258	188,819
Other Benefits
Defined Benefit Plan Disclosure [Line Items]
Other assets	0	0
Payroll and benefit-related liabilities	(2,725)	(3,125)
Pension and postretirement benefit liabilities	(24,079)	(28,796)
Accumulated other comprehensive loss (gain)	(2,847)	(1,617)
Amounts recognized in balance sheet	$ (29,651)	$ (33,538)

Pension and other postretirem_8

Pension and other postretirement benefits - Amounts recognized in accumulated other comprehensive (income) loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan, Chance in Amounts Recognized in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance, accumulated other comprehensive (income) loss, net of tax	$ 297,298
Impact of currency translation, accumulated other comprehensive (income) loss, net of tax	63,191	$ (59,758)	$ (4,195)
Ending balance, accumulated other comprehensive (income) loss, net of tax	346,959	297,298
Pension
Defined Benefit Plan, Chance in Amounts Recognized in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance, prior service cost (credit)	205	173
Net amortization and deferral, prior service cost	(5)	(15)
Actuarial changes in benefit obligation, prior service cost	0	0
Defined benefit plan, plan amendments		47
Impact of currency translation, prior service cost (credit)	0	0
Ending balance, prior service cost (credit)	200	205	173
Beginning balance, net (gain) or loss	232,335	213,816
Net amortization and deferral, net (gain) or loss	(8,584)	(7,432)
Actuarial changes in benefit obligation, net gain (loss)	(4,965)	25,100
Defined benefit plan, net (gain) or loss on plan amendments		0
Impact of currency translation, net (gain) or loss	(847)	851
Ending balance, net (gain) or loss	217,939	232,335	213,816
Beginning balance, deferred taxes	(80,657)	(76,270)
Net amortization and deferral, deferred taxes	1,999	1,738
Actuarial changes in benefit obligation, deferred taxes	1,148	(5,875)
Defined benefit plan, plan amendments on deferred taxes		(9)
Impact of currency translation, deferred taxes	237	(241)
Ending balance, deferred taxes	(77,273)	(80,657)	(76,270)
Beginning balance, accumulated other comprehensive (income) loss, net of tax	151,883	137,719
Net amortization and deferral, accumulated other comprehensive (income) loss, net of tax	(6,590)	(5,709)
Actuarial changes in benefit obligation, accumulated other comprehensive income (loss), net of tax	(3,817)	19,225
Plan amendments in benefit obligation, accumulated other comprehensive income loss, net of tax		38
Impact of currency translation, accumulated other comprehensive (income) loss, net of tax	(610)	610
Ending balance, accumulated other comprehensive (income) loss, net of tax	140,866	151,883	137,719
Other Benefits
Defined Benefit Plan, Chance in Amounts Recognized in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance, prior service cost (credit)	(4,669)	7
Net amortization and deferral, prior service cost	1,017	(18)
Actuarial changes in benefit obligation, prior service cost	0	0
Defined benefit plan, plan amendments		(4,658)
Ending balance, prior service cost (credit)	(3,652)	(4,669)	7
Beginning balance, net (gain) or loss	3,052	1,909
Net amortization and deferral, net (gain) or loss	41	179
Actuarial changes in benefit obligation, net gain (loss)	(2,288)	964
Defined benefit plan, net (gain) or loss on plan amendments		0
Ending balance, net (gain) or loss	805	3,052	1,909
Beginning balance, deferred taxes	(9)	(825)
Net amortization and deferral, deferred taxes	(243)	(37)
Actuarial changes in benefit obligation, deferred taxes	523	(223)
Defined benefit plan, plan amendments on deferred taxes		1,076
Ending balance, deferred taxes	271	(9)	(825)
Beginning balance, accumulated other comprehensive (income) loss, net of tax	(1,626)	1,091
Net amortization and deferral, accumulated other comprehensive (income) loss, net of tax	815	124
Actuarial changes in benefit obligation, accumulated other comprehensive income (loss), net of tax	(1,765)	741
Plan amendments in benefit obligation, accumulated other comprehensive income loss, net of tax		3,582
Ending balance, accumulated other comprehensive (income) loss, net of tax	$ (2,576)	$ (1,626)	$ 1,091

Pension and other postretirem_9

Pension and other postretirement benefits - Weighted average assumptions used in determining benefit obligations (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Pension
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	2.80%	2.50%
Rate of compensation increase	2.80%	2.80%
Other Benefits
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	2.70%	2.30%
Initial healthcare trend rate	6.00%	6.40%
Ultimate healthcare trend rate	4.50%	4.50%

Pension and other postretire_10

Pension and other postretirement benefits - Fair values of pension plan assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Maximum percentage of net assets invested in emerging market	35.00%
Minimum
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Effective average duration to maintain	3 years
Maximum
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Effective average duration to maintain	10 years
Emerging markets debt fund
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Percentage of net assets invested in foreign equity securities	80.00%
Small and Mid-Sized Companies \| Equity Securities \| U.S. Russell 2500 Index
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Percentage of net assets invested	80.00%
Foreign Companies
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Percentage of net assets invested in foreign equity securities	80.00%
Fair Value, Measurements, Recurring
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	$ 469,793	$ 457,626
Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	459,105	429,882
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	439,093	414,299
Fair Value, Measurements, Recurring \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	879	5,094
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	19,133	10,489
Fair Value, Measurements, Recurring \| Fair Value Measured at Net Asset Value Per Share
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	10,688	27,744
Fair Value, Measurements, Recurring \| Cash \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	923	582
Fair Value, Measurements, Recurring \| Cash \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	923	582
Fair Value, Measurements, Recurring \| Cash \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Cash \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Money market funds \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	6	12
Fair Value, Measurements, Recurring \| Money market funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	6	12
Fair Value, Measurements, Recurring \| Money market funds \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Money market funds \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Managed Volatility \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	57,252	85,974
Fair Value, Measurements, Recurring \| Managed Volatility \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	57,252	85,974
Fair Value, Measurements, Recurring \| Managed Volatility \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Managed Volatility \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| U.S. Small/Mid-Cap Equity \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	7,532	11,780
Fair Value, Measurements, Recurring \| U.S. Small/Mid-Cap Equity \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	7,532	11,780
Fair Value, Measurements, Recurring \| U.S. Small/Mid-Cap Equity \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| U.S. Small/Mid-Cap Equity \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| World equity (excluding U.S.) \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	34,287	59,467
Fair Value, Measurements, Recurring \| World equity (excluding U.S.) \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	34,287	59,467
Fair Value, Measurements, Recurring \| World equity (excluding U.S.) \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| World equity (excluding U.S.) \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Intermediate duration bond fund \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	101,363	63,376
Fair Value, Measurements, Recurring \| Intermediate duration bond fund \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	101,363	63,376
Fair Value, Measurements, Recurring \| Intermediate duration bond fund \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Intermediate duration bond fund \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Long duration bond fund \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	171,919	98,996
Fair Value, Measurements, Recurring \| Long duration bond fund \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	171,919	98,996
Fair Value, Measurements, Recurring \| Long duration bond fund \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Long duration bond fund \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Corporate bond fund \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	7,607	13,469
Fair Value, Measurements, Recurring \| Corporate bond fund \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	7,607	13,469
Fair Value, Measurements, Recurring \| Corporate bond fund \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Corporate bond fund \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Emerging markets debt fund \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	7,605	11,412
Fair Value, Measurements, Recurring \| Emerging markets debt fund \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	7,605	11,412
Fair Value, Measurements, Recurring \| Emerging markets debt fund \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Emerging markets debt fund \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Corporate, government and foreign bonds \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	50,599	35,582
Fair Value, Measurements, Recurring \| Corporate, government and foreign bonds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	50,599	35,582
Fair Value, Measurements, Recurring \| Corporate, government and foreign bonds \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Corporate, government and foreign bonds \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Absolute return credit fund \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	671
Fair Value, Measurements, Recurring \| Absolute return credit fund \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0
Fair Value, Measurements, Recurring \| Absolute return credit fund \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	671
Fair Value, Measurements, Recurring \| Absolute return credit fund \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0
Fair Value, Measurements, Recurring \| Asset backed – home loans \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	208	261
Fair Value, Measurements, Recurring \| Asset backed – home loans \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Asset backed – home loans \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	208	261
Fair Value, Measurements, Recurring \| Asset backed – home loans \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Contract with insurance company \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	19,130	10,485
Fair Value, Measurements, Recurring \| Contract with insurance company \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Contract with insurance company \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Contract with insurance company \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	19,130	10,485
Fair Value, Measurements, Recurring \| Other \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	3	4
Fair Value, Measurements, Recurring \| Other \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Other \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Other \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	$ 3	4
Fair Value, Measurements, Recurring \| Common equity securities \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		29,592
Fair Value, Measurements, Recurring \| Common equity securities \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		29,592
Fair Value, Measurements, Recurring \| Common equity securities \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		0
Fair Value, Measurements, Recurring \| Common equity securities \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		0
Fair Value, Measurements, Recurring \| Multi asset funds \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		8,890
Fair Value, Measurements, Recurring \| Multi asset funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		4,057
Fair Value, Measurements, Recurring \| Multi asset funds \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		4,833
Fair Value, Measurements, Recurring \| Multi asset funds \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		$ 0

Pension and other postretire_11

Pension and other postretirement benefits - Expected benefit payments (Detail) $ in Thousands	Dec. 31, 2021USD ($)
Pension
Schedule Of Pension Expected Future Benefit Payments [Line Items]
2022	$ 22,732
2023	22,859
2024	23,583
2025	23,976
2026	24,622
Years 2027 — 2031	127,007
Other Benefits
Schedule Of Pension Expected Future Benefit Payments [Line Items]
2022	2,723
2023	2,630
2024	2,432
2025	2,348
2026	2,073
Years 2027 — 2031	$ 7,388

Commitments and contingent li_2

Commitments and contingent liabilities - Additional Information (Detail) - USD ($) $ in Millions	Feb. 17, 2021	Sep. 26, 2021	Dec. 31, 2021	Dec. 31, 2020
Loss Contingencies [Line Items]
Money damages sought	$ 66.9
Reversal accrued penalties and interest		$ 3
Essential Medical Inc
Loss Contingencies [Line Items]
Payment for contingent consideration liability			$ 17.4
Minimum
Loss Contingencies [Line Items]
Estimated time frame over which accrued amounts may be paid out			10 years
Minimum \| China investigation, unpaid tariffs
Loss Contingencies [Line Items]
Loss contingency accrual, unpaid tariff, penalties percentage			30.00%
Loss contingency, estimate of possible loss			$ 3
Maximum
Loss Contingencies [Line Items]
Estimated time frame over which accrued amounts may be paid out			15 years
Maximum \| China investigation, unpaid tariffs
Loss Contingencies [Line Items]
Loss contingency accrual, unpaid tariff, penalties percentage			200.00%
Loss contingency, estimate of possible loss			$ 20
Accrued Liabilities
Loss Contingencies [Line Items]
Waste disposed accrued liability			2	$ 1.6
Contingency reserve for litigation			0.2	0.3
Other Liabilities
Loss Contingencies [Line Items]
Waste disposed accrued liability			$ 4.1	$ 5.2

Business segments and other i_3

Business segments and other information - Segment Result (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Revenues From External Customers And Long Lived Assets [Line Items]
Number of reportable segments \| segment	4
Net revenues	$ 2,809,563	$ 2,537,156	$ 2,595,362
Operating profit	628,095	423,068	427,254
Depreciation and amortization	237,362	227,252	218,369
Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Operating profit	659,948	578,829	545,441
Segment Reconciling Items
Revenues From External Customers And Long Lived Assets [Line Items]
Operating profit	(31,853)	(155,761)	(118,187)
Americas
Revenues From External Customers And Long Lived Assets [Line Items]
Depreciation and amortization	164,102	151,111	153,419
Americas \| Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	1,659,309	1,465,035	1,492,274
Operating profit	424,225	401,391	319,933
EMEA
Revenues From External Customers And Long Lived Assets [Line Items]
Depreciation and amortization	45,022	47,012	44,328
EMEA \| Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	606,807	584,859	588,043
Operating profit	94,865	81,348	94,424
Asia
Revenues From External Customers And Long Lived Assets [Line Items]
Depreciation and amortization	11,140	13,594	14,072
Asia \| Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	297,766	267,016	294,328
Operating profit	84,648	51,238	73,090
OEM
Revenues From External Customers And Long Lived Assets [Line Items]
Depreciation and amortization	17,098	15,535	6,550
OEM \| Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	245,681	220,246	220,717
Operating profit	$ 56,210	$ 44,852	$ 57,994

Business segments and other i_4

Business segments and other information - Total net revenues and total net property, plant and equipment by geographic region (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Net revenues	$ 2,809,563	$ 2,537,156	$ 2,595,362
Property, plant and equipment, net	443,758	473,912
U.S.
Segment Reporting Information [Line Items]
Net revenues	1,769,488	1,567,144	1,606,248
Property, plant and equipment, net	206,876	234,186
Europe
Segment Reporting Information [Line Items]
Net revenues	665,000	646,577	652,069
Asia Pacific
Segment Reporting Information [Line Items]
Net revenues	263,022	230,267	241,278
All other
Segment Reporting Information [Line Items]
Net revenues	112,053	93,168	$ 95,767
Property, plant and equipment, net	94,870	98,636
Malaysia
Segment Reporting Information [Line Items]
Property, plant and equipment, net	72,541	71,760
Mexico
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 69,471	$ 69,330

SCHEDULE II - VALUATION AND Q_2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS - ALLOWANCE FOR DOUBTFUL ACCOUNTS (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 12,900
Balance at End of Year	10,800	$ 12,900
Allowance for Doubtful Accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	12,875	9,055	$ 9,348
Additions Charged to Income	1,542	3,798	1,680
Accounts Receivable Write-offs	(3,001)	(1,336)	(1,739)
Translation and Other	(617)	1,358	(234)
Balance at End of Year	$ 10,799	$ 12,875	$ 9,055

SCHEDULE II - VALUATION AND Q_3

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS - DEFERRED TAX ASSET VALUATION ALLOWANCE (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 155,008
Balance at End of Year	143,177	$ 155,008
Valuation Allowance of Deferred Tax Assets
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	155,008	119,233	$ 143,971
Additions Charged to Income	7,770	30,640	31,564
Accounts Receivable Write-offs	(15,384)	(59)	(55,797)
Translation and Other	(4,217)	5,194	(505)
Balance at End of Year	$ 143,177	$ 155,008	$ 119,233